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ABSTRACT 
Coronaviridae family is composed of a number of ribonucleic acid (RNA)-containing viruses 
currently classified into two genera, the coronavirus and torovirus. The family is classified together 
with the Arteviridae in the order Nidovirales. Coronaviruses are enveloped single stranded positive 
sense RNA viruses about 80-160 nm in diameter. The coronavirus is, as in the case of all positive 
sense RNA virus, a messenger, and the naked RNA is infectious. The 5′-two thirds of the genome 
encodes for a polyprotein that contains all the enzymes necessary for replication, whereas the 3′-one 
third encodes for all the structural proteins that mediate viral entry into the host cell. The structural 
proteins include spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins. 
 Nucleocapsid protein is one of the most crucial structural components of coronaviruses; 
hence major attention has been focused on characterization of this protein. Some laboratories have 
demonstrated that this protein interferes with different cellular pathways, thus implying it to be a 
key regulatory component of the virus (Zakhartchouk, Viswanathan et al. 2005). Furthermore, it has 
been shown that severe acute respiratory syndrome (SARS)-N protein interacts with cellular 
proteins, including cyclophilin A (CypA), heterogenous nuclear ribonucleoprotein (hnRNP) A1, 
human ubiquitin-conjugating enzyme, cyclin dependent kinase (CDK)-cyclin complex protein, 
Ikappaßalpha (IkBα), cytochrome (Cyt) P450 etc. For the purpose of this study, the focus is based 
on CypA interaction with human coronavirus (HCoV) NL63-N protein. These interactions might 
play a role in the pathology of HCoV-NL63. Using glutathione-S-transferase (GST), the interaction 
of CypA with the nucleocapsid protein can be clearly demonstrated to be direct and specific. Since 
the N protein is involved in viral RNA packaging to form a helical core, it is suffice to say that both 
NL63-N and CypA are possibly within the HCoV-NL63 replication/transcription complex and 
NL63-N/human CypA interaction might function in the regulation of HCoV-NL63 RNA synthesis.   
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In addition, the results will demonstrate that HCoV-NL63-N has only a specific domain for 
interacting with CypA.  
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1.1. BACKGROUND 
Coronavirus is a genus of animal virus belonging to the family Coronaviridae. The name 
"coronavirus" is derived from the Greek word κορώνα, meaning “crown”. The virus envelope is 
characterized by a ring of small bulbous structures when analyzed by electron microscopy and this 
gives the virus its characteristic appearance (Liu, Yang et al. 2007; Versteeg, van de Nes et al. 
2007; Lin, Feng et al. 2008). This morphology is actually formed by the viral spike (S) peplomers, 
which are proteins that populate the surface of the virus and determine host tropism (Buchholz, 
Bukreyev et al. 2004). Coronaviruses are currently classified into two genera, the coronavirus and 
torovirus. They, together with Arteriviridea are grouped in the order Nidovirales, named for the 
Latin nidus, meaning “nest”, as all viruses in this order produce a 3′ co-terminal nested set of 
subgenomic mRNA′s during infection (Yeung, Yamanaka et al. 2006). In comparison to toroviruses 
that have a tubular nucleocapsid that appears toroidal in shape, coronaviruses have a helical 
nucleocapsid 10-20 nm in diameter in their virion. In addition, coronavirus virion is roughly 
spherical in shape, whereas torovirus virion is disk shaped or rod shaped. Contrary to well-studied, 
described and published data on the coronavirus, the torovirus, which is comprised of one pathogen 
of horses, one pathogen of cattle, a presumptive human torovirus, and a possible torovirus of swine, 
have only been described recently. About three groups of coronaviruses are recognized based on 
their serologic and genotypic characteristics: group 1 and 2 contain mammalian viruses, whereas 
group 3 contains only avian viruses (de Haan, Haijema et al. 2008; Woo, Lau et al. 2009; 
Jackwood, Boynton et al. 2010). Group 2 viruses are also characterized by the presence of a gene 
encoding the hemaglutin esterase (HE) protein, which is absent in the other groups.  
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Coronaviruses are enveloped single stranded positive sense RNA viruses about 80-160 nm in 
diameter. Coronaviruses are somewhat larger in their genome size compared to toroviruses. All 
coronaviruses employ a common genome organization. The 3′-one third of the genome encodes for 
structural proteins. These structural proteins include spike (S), envelope (E), membrane (M), and 
nucleocapsid (N) proteins. For the purpose of this study, the structural protein of interest is the 
nucleocapsid protein. Here we compare the characteristics of severe acute respiratory syndrome 
coronavirus (SARS)-N with NL63-N, so that we can elucidate whether NL63-N will exhibit the 
same characteristics as SARS-N.  
 
1.2. DISCOVERY OF CORONAVIRUSES 
The history of coronaviruses began in 1965 when Tyrrel and Bynoe found that they could passage a 
virus named B814. This virus was accidentally discovered in human embryonic tracheal organ 
cultures obtained from the respiratory tract of an adult with a common cold. Unfortunately, Tyrrel 
and Bynoe could not grow the virus in tissue culture at the time due to its unusual properties 
(Tyrrell and Bynoe 1958; Tyrrell, Bynoe et al. 1959; Bynoe, Hobson et al. 1961). However, at 
about the same time, Hamre and Procknow were able to grow the virus in tissue culture from 
volunteers with colds. The literature indicates that both B814 and Hamre′s virus were ether-
sensitive and therefore presumably required an envelope for infectivity (Kennedy and Johnson-
Lussenburg 1975; Schreiber, Kamahora et al. 1989). Surprisingly, these two viruses were not 
related to myxo- or paramyxoviruses that have a lipid-containing coat. Using a technique that is 
similar to Terryl and Beynoe, Hamre and Procknow  reported the recovery of multiple strains of 
ether-sensitive agents from the human respiratory tract (Tyrrell, Bynoe et al. 1960). These viruses 
were termed OC to designate that they were grown in organ cultures.  
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Within the same time, Almeida and Tyrrel performed electron microscopy on fluids from 
organ cultures infected with B814 and found particles that resemble the infectious bronchitis virus 
(IBV) of chicken (Kapikian 1975). Hamre′s 229E agent and the OC viruses identified by McIntosh 
had a similar morphology. The coronavirus group was officially accepted as a new genus in the late 
1960s after Tyrrel demonstrated human strains and a similar number of animal viruses to be 
morphologically similar as seen through electron microscopy (Kapikian 1975). However, B814 
strain was shown by Bradburne to be serologically non-identical with either OC43 or 229E. Human 
and animal coronaviruses were segregated into 3 broad groups based on their antigenic and genetic 
make-up. Group 1 contained coronavirus 229E and other viruses. Group II contained OC43 and 
group III was made up of avian IBV and other related viruses. 
In the three decades after discovery, human strains OC43 and 229E were exclusively 
studied largely because they were the easiest ones to work with. Given the enormous variety of 
animal coronaviruses, severe acute respiratory syndrome (SARS) emerged in 2002-2003 as a 
coronavirus from Southern China and spread throughout the world (Wang, Ji et al. 2003; Lu, Zhao 
et al. 2004; Hao, Chen et al. 2006). Sequencing of SARS differed sufficiently from any of the 
known human or animal coronaviruses. It is unclear how the virus entered the human population 
and palm civets were suspected to be the natural reservoir of the virus. Sequence analysis of the 
virus isolated from Himalayan palm civets revealed that this virus contained a 29-nucleotide 
sequence that is not found in most human isolates, in particular those involved in the worldwide 
spread of the epidemic (Graham and Baric 2010).  
Following the outbreak of SARS in 2002-2003, new human coronaviruses (HCoV) have 
been discovered. After the discovery of SARS it became evident that highly pathogenic strains of 
coronavirus can still emerge and as a result these viruses have received global attention. Through 
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increasing efforts in scientific research five human coronaviruses are now known, including OC43, 
229E, SARS HCoV, HCoV NL63 and HCoV HKU1. HCoV NL63 was discovered in 2004 by Lia 
van der Hoek in Amsterdam from a 7 month old girl presenting with respiratory symptoms. Shortly 
after, Fouchier et al. reported the identification of a coronavirus NL isolated from an 8 month old 
boy with pneumonia and grown from a clinical sample that was obtained in April 1988. Genome 
sequence analysis demonstrated the virus belongs to group 1 and is closely related to HCoV NL63 
(Lin, Feng et al. 2011). A few months later, Esper et al. found evidence of a human respiratory 
coronavirus from children younger than 5 years of age, which was designated HCoV New Haven 
coronavirus (HCoV NH). This was achieved through the use of molecular probes that targeted 
conserved regions of the coronavirus genome (Shao, Guo et al. 2007). This approach was based on 
the theory that the viral replicase gene of all coronavirus has conserved genetic sequences that 
encode indispensable, essential functions and that these sequences could be targeted for virus 
identification and discovery. It is now accepted that these three viruses are all essentially the same 
virus. 
To date, the latest discovery is a group II coronavirus, known as HCoV HKU1, which is 
closely related to OC43. It was discovered from a 71 year old man whom had returned from a 
previously SARS-endemic area in China presenting with fever and productive cough (Chan, Woo et 
al. 2008; Chan, Tse et al. 2009; Woo, Lau et al. 2009). SARS screening for this patient was 
negative, and the coronavirus sequence was amplified by reverse transcription-polymerase chain 
reaction (RT-PCR) from respiratory specimen using primers that targeted conserved regions of the 
viral replicase.     
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1.3. HUMAN CORONAVIRUS NL63 
1.3.1. Discovery 
Human coronavirus NL63 (HCoV NL63) was discovered in 2004 following the outbreak of the 
deadly SARS outbreak in China. After this outbreak coronaviruses received international attention, 
and through increasing efforts on research new human coronaviruses have been discovered recently, 
and HCoV NL63 in the Netherlands is amongst those new discoveries. In 2004, Lia van der Hoek et 
al. reported the discovery of a group I coronavirus, HCoV NL63, from a 7 month old girl with 
coryza, conjunctivitis, fever, and bronchiolitis (Shao, Guo et al. 2007; Dijkman, Jebbink et al. 2008; 
Woo, Lau et al. 2009).  
 
1.3.2. Symptoms and prevalence  
Coronavirus infection of human was usually not associated with severe diseases, but following the 
discovery of SARS it became evident that highly pathogenic strains of human coronavirus can still 
evolve. Human coronaviruses, except SARS-CoV, generally cause disease much like the common 
cold, but they have also been associated with more severe lower respiratory tract conditions, 
especially in frail patients (Woo, Lau et al. 2005; Dijkman, Jebbink et al. 2006; Shao, Guo et al. 
2007). This has been implicated more commonly with SARS which causes both upper and lower 
respiratory infections. The viruses can infect both the enteric and central nervous system, but they 
are predominantly involved with respiratory illnesses. They are thought to be transmitted by direct 
contact, droplets, or contaminated human excreta. In the latter, precautionary measures should be 
instigated immediately and accordingly. The general clinical symptoms associated with the 
coronavirus include bronchiolitis, rhinitis, pharyngitis, pneumonia, fever, and conjunctivitis 
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(Hofmann, Simmons et al. 2006). However, the clinical symptoms that are specifically associated 
with NL63 still need to be determined. Patients suspected of being infected with the coronavirus 
need to be quarantined and treated with intense care to minimize transmission to others. The same 
can be said about the very recently described HCoV HKU1, which was identified in a 71 year old 
patient with chronic obstructive airways disease (COPD) (Chan, Woo et al. 2008). 
 
1.3.3. Seasonal incidence 
During the 2002-2003 outbreaks, SARS infection was reported in 29 countries in North America, 
South America, Europe and Asia. Overall 8 098 infected individuals were identified, with 774 
SARS-related fatalities (St-Jean, Jacomy et al. 2004; Patrick, Petric et al. 2006; Bartlam, Xu et al. 
2007). Ongoing research using serologic techniques has resulted in a considerable amount of 
information regarding the epidemiology of the human respiratory coronavirus. Literature indicates 
that in temperate climates, respiratory coronavirus infections occur more often in the winter and 
spring than in summer and autumn. There is strong evidence that the spread of this virus is 
seasonal, and is prevalent during the winter season (St-Jean, Jacomy et al. 2004; Wang, Li et al. 
2004). A study that was conducted by Vabret et al. in 2002-2003 indicated that the highest 
prevalence of coronaviruses was in February (In the northern hemisphere during winter). Some 
studies have shown that coronavirus infection contributes as much as 35 % of the total respiratory 
viral activity during epidemics (Stadler, Masignani et al. 2003; Wong and Yuen 2005). Overall, the 
proportion of adult colds produced by coronaviruses was estimated at 15 %. After the discovery of 
OC43 and 229E it was revealed that the viruses demonstrated periodicity, with large epidemics 
occurring at 2-3 year intervals. Strain 229E tended to be epidemic throughout the United States, 
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whereas the OC43 strain was more predisposed to localized outbreaks (Lau, Woo et al. 2004; 
Patrick, Petric et al. 2006). 
  
1.3.4. Genome and genomic replication  
All coronaviruses employ a common genome organization as indicated in figure 1.1. The genome 
that is specifically associated with HCoV NL63 has the following gene order: 1a-1b-S-ORF3-E-M-
N (Wang, Li et al. 2004). The 5′- two thirds of the genome is comprised of replicase gene (22 kbp) 
whereas the 3′- one third constitutes the genes that encode for structural proteins.   
 
Figure 1.1: Schematic representation of the genomic organization of coronaviruses. The 5′- two 
thirds of the genome represent two overlapping open reading frames, known as ORF 1a and ORF 
1b. These polyproteins constitute approximately 22 kbp of the entire genome. The 3′- one third of 
the genome, on the other hand, is comprised of structural proteins (adapted from Wang, Li et al. 
2004). 
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The replicase gene encompasses the 5′-two thirds of the genome and is comprised of two 
overlapping open reading frames (ORFs), ORF 1a and ORF 1b (Woo, Huang et al. 2005; Kim, Lee 
et al. 2006; Ren, Li et al. 2006). The replicase is the first protein to be made and once the gene 
encoding the replicase is translated the translation is stopped by a stop codon. This is known as a 
nested transcript, where the transcript only encodes one gene, it is monocistronic. Expression of the 
replicase gene is known to be mediated by translation of the genomic RNA that gives rise to  the 
biosynthesis of two large polyproteins, pp 1a (encoded by ORF 1a) and pp 1ab (encoded by ORF 1a 
and ORF 1b using a ribosomal frameshift at the ORF 1a/1b junction) (Wang, Li et al. 2004). These 
non-structural proteins are known to have multiple enzymatic functions and might include types of 
enzymes that are common components of the replication machinery of positive-strand RNA viruses: 
an RNA-dependent RNA polymerase activity, a 3C-like serine protease activity, a papain-like 
protease 2 activity, and a superfamily-1 helicase activity (Dijkman, Jebbink et al. 2006). These 
enzymes are known to be less common in positive-sense RNA viruses, and may therefore be related 
to the unique properties of coronavirus replication and transcription (Ren, Li et al. 2006). 
Expression of the structural gene region is mediated via discontinuous transcription of 
subgenomic mRNAs, a hallmark of coronavirus gene expression (Zhang, Guy et al. 2007). The 
capped and polyadenylated RNA is translated into distinct polyproteins that are required for the 
replication and production of subgenomic mRNAs.  The initial polyprotein terminates at a stop 
codon approximately 12 kb from the 5′ end of the RNA. However, the occurrence of the frequent 
ribosomal frame shift causes the frame to shift and thus translation continues to the end of the RNA 
replicase encoding region at 22 kb. The resulting polyproteins are cleaved by virus encoded 
proteases known as one papain-like and serine-like protease (Chen, Wang et al. 2007). The 
mechanism by which subgenomic RNAs are produced has been difficult to determine. The first 
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mechanism proposed was primer-directed synthesis using the negative sense RNA template. In this 
model, a primer of about 60 nucleotides is transcribed from the 3′ end of the template, which is 
identical to the 5′ end of the genomic RNA. The primer is proposed to dissociate from the template 
and to be used by the viral RNA synthetase to reinitiate synthesis at any of the several subgenomic 
promoters in the (-) RNA template. Evidence to this model includes the fact that each subgenomic 
RNA has at its 5′ end the same 60 nucleotides that are present at the 5′ end of the genomic RNA, 
and that there is a short sequence element present at the beginning of each gene that could act as an 
acceptor of the primer (Shulla, Heald-Sargent et al. 2011). 
   A more recent model, however, proposes that the bulk of the subgenomic mRNA are 
produced by independent replication of these RNAs as replicons. Such replication is thought to be 
possible because the mRNA contains both the 5′ and 3′ sequences present in the genomic RNA, and 
therefore possess the promoters required for replication. Evidence to this model includes the fact 
that both positive and negative sense RNAs are present in infected cells (Shulla, Heald-Sargent et 
al. 2011). 
The structural proteins include spike, envelope, membrane and nucleocapsid proteins. The 
number of subgenomic mRNA produced by a particular coronavirus usually exceeds the number of 
encoded structural proteins and consequently, coronaviruses are able to express additional, so-called 
accessory genes (Dijkman, Jebbink et al. 2006; Zhang, Guy et al. 2007; Frieman, Ratia et al. 2009). 
These genes are interspersed between the structural genes and their number and location varies 
within the coronavirus genome (Dijkman, Jebbink et al. 2006). The function of these accessory 
proteins are largely unknown, however, reverse genetic analysis of mouse hepatitis virus (MHV) 
suggest that they are not required for virus replication (Nedialkova, Ulferts et al. 2009). 
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1.3.5. Characterized genes 
The coronavirus particles consist of four structural proteins that are encoded in the 3′- one third end 
of the genome: spike (S), membrane (M), nucleocapsid (N) and envelope (E). They also encode for 
non-structural proteins in the 5′- two thirds of the genome. Some of these proteins are hydrophobic 
while others are hydrophilic in nature. The hydrophilic proteins are thought to have antigenic 
properties since they are exposed to the host immune defense mechanism, while hydrophobic 
proteins are thought to be non-immunogenic. Several studies have shown that most of the 
nonstructural proteins in SARS are hydrophilic in nature except NSP1, NSP3, X1, X4, which are 
predicted to have some transmembrane domains, and that most of the structural proteins are 
hydrophobic except the N protein which is predicted to be highly hydrophilic (Campanacci, Egloff 
et al. 2003; Nedialkova, Ulferts et al. 2009). These attributes may to some extent reflect the 
function that is being performed by the viral protein as well as its distribution within the virion. All 
the nonstructural proteins are synthesized in the cytosol of host cells and then carry out the function 
of virus replication, including viral RNA replication, viral mRNA transcription and editing, virion 
assembly, and inhibition of host cell protein synthesis (Neuman, Joseph et al. 2008). Such 
functional requirements may drive the nonstructural proteins to take soluble form, i.e 
hydrophilicity.     
The structural proteins like E and M are on the surface of a virion, which necessitate them 
to take hydrophobic form to form a non-polar barrier between the N inside the virion and the outer 
environment. An exception to this is the S glycoprotein, which is predicted to have a short piece of 
transmembrane domain near its carboxy (C)-terminus (Kang, Yang et al. 2006; Schaecher, 
Diamond et al. 2008; Yan, Tan et al. 2009). This transmembrane domain may separate the inner 
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part from the outer part.  For the exception of structural proteins, a hydrophilic form for S- protein 
is necessary to facilitate an interaction of this nature. 
The M protein is a component of the viral envelope that plays a central role in virus 
morphogenesis and assembly via its interactions with other viral proteins. The E protein, on the 
other hand, has some similar functions as M protein and there is known interactions between the 
two proteins during viral replication (Liu, Sun et al. 2010). The E protein seems to play a crucial 
role in creating the membrane curvature needed to acquire the rounded, stable and infectious 
particle phenotype. In addition, it induces the formation of hydrophilic pores in cellular membranes 
(Ren, Li et al. 2006; Yeung, Yamanaka et al. 2006). The S protein mediates viral entry into host 
cells during infection. The S protein is a type 1 membrane glycoprotein that can be divided into 2 
domains viz. S1 (1-717 aa) and S2 (718-1356 aa) based on its similarity to other coronaviruses 
(Hofmann, Simmons et al. 2006; Lin, Feng et al. 2011). The S1 domain is responsible for binding to 
cellular receptors, whilst S2 is mainly involved in membrane fusion during viral entry (Kam, 
Okumura et al. 2009).   
 
1.4. HUMAN CORONAVIRUS NUCLEOCAPSID GENE 
Coronavirus N proteins are basic proteins that encapsulate viral genomic RNA to form part of the 
virus structure. SARS-N protein is known to be highly antigenic and associated with several host 
cell interactions (Stohlman, Fleming et al. 1983; Hogue and Brian 1986; Zhou, Liu et al. 2008). 
SARS-N enters the host cell together with the viral RNA and interferes with several cellular 
processes. These interactions might have a role in the pathology of SARS. Previous studies have 
shown that protein-protein interactions are critical for viral assembly. Determination of these 
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interactions and identification of amino acid sequences responsible for such interactions are 
necessary for the elucidation of the molecular mechanisms of SARS replication and rationalization 
of anti-SARS therapeutic intervention. SARS-N has been shown to interact with cellular proteins, 
including cyclophilin A, human cellular heterogenous nuclear ribonucleoprotein A1 (hnRNP A1), 
and cyclin dependent kinase (CDK)-cyclin complex proteins (Luo, Luo et al. 2004; Luo, Chen et al. 
2005; Surjit, Liu et al. 2006; Li, Lai et al. 2011).  
The extensively characterized SARS-N protein can be divided into 3 putative domains: N-
terminal domain (NTD), RNA binding domain (RBD), and C-terminal domain (CTD). Structural 
studies of the NTD (residues 45-181) of the SARS-N protein have shown that it acts as a putative 
RNA-binding domain, whereas the CTD (residues 248-365) acts as a dimerization domain (Tang, 
Wu et al. 2005). Similar structures to those of the SARS-CoV N protein have also been reported for 
the NTD and CTD of avian infectious bronchitis virus (IBV) N protein indicating that the 
aforementioned structural arrangements are common among coronaviruses (Cavanagh 2003). These 
include NTD residues 19-162 in IBV, analogous to residues 45-181 in SARS-CoV and residues 
219-349 in IBV being analogous to residues 248-365 in SARS-CoV (He, Du et al. 2005). This 
indicates that some degree of conserved regions within the Coronaviridaea family, but the 
significance remains unclear. The NTD and CTD are believed to play an imperative role in 
interaction with other proteins. Surprisingly, the mid-portion of the protein interacts with hnRNP 
A1 (Luo, Chen et al. 2005). This association was initially established in mouse hepatitis virus 
(MHV)-N protein studies. The binding site of hnRNP A1 with MHV-N was determined in two 
regions of the protein using yeast two hybrid assay. These included amino (N)-terminal region (1-
292) and C-terminal end (391-455). The association was mapped to the 161-210 amino acid 
fragment of SARS-N and to the 203-320 glycine-rich region of hnRNP A1 (Luo, Chen et al. 2005). 
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The SARS nucleocapsid protein has been shown to have only one binding domain for interacting 
with hnRNP A1. In contrast, the MHV has two binding domains that are involved in MHV-
N/hnRNP A1 interaction, thereby suggesting that the SARS-N might carry out a different binding 
mode to human hnRNP A1. In addition to hnRNP A1, human cyclophilin A also exhibits high 
binding affinity to SARS-CoV-N protein. This interaction occurs via the Trp302-Pro310 loop (Luo, 
Luo et al. 2004). However, the significance of this interaction has not been established. 
 
1.5. CYCLOPHILIN A 
1.5.1. Cellular functions  
Cyclophilin A (CypA) is a peptidyl-prolyl cis/trans isomerase (PPIA) that is involved in several 
signaling events of eukaryotic cells. It can either act as prolyl bond isomerization catalyst, or it 
can form stoichometric complexes with target proteins. About 16 different cyclophilin molecules 
are encoded in the human genome. However, these proteins exhibit differences in tissue 
distribution, sub-cellular localization and relative abundance, but in terms of their 3-D structure 
and PPIAse activity they share similarities (Thai, Renesto et al. 2008). Several studies have 
shown increased expression levels of CypA in tumor cells. Up-regulation of CypA has been 
found to be a common phenomenon in several tumor types, including hepatocellular carcinoma. 
However, the role of CypA in tumor cells remains obscure. Some studies have revealed that 
CypA can up-regulate the expression of many cytokines and drug resistance related genes (Chen, 
Zhang et al. 2008). Moreover, it has been shown that elevated CypA expressions contribute to 
drug resistance. This may play a role in clinical resistance to chemotherapy in cancer patients 
(Chen, Zhang et al. 2008).  
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CypA has been shown to be secreted in cells in response to inflammatory stimuli and is a 
potent neutrophil and eosinophil chemo-attractant both in vitro and in vivo (Yang, Lu et al. 
2008). The signaling activity is via CD147 cell surface receptors, but the mechanism underlying 
CypA-mediated signaling and chemotaxis remain unclear. CypA plays key roles in several 
different aspects of cellular physiology including the immune response, transcription, 
mitochondrial function, cell death, and chemotaxis (Watashi and Shimotohno 2007). In addition 
to these cellular events, a number of reports demonstrate that CypA plays a critical role in the life 
cycle of viruses, especially human immune virus (HIV)-1, SARS and hepatitis C virus (HCV). 
These viruses are significant causes of morbidity and mortality worldwide, but current therapies 
are often insufficient. CypA may provide a novel therapeutic target for the management and 
possibly cure of these diseases, especially coronaviruses (Luo, Luo et al. 2004).  
 
1.5.2. Interaction with viral proteins  
Cyclophilin A (CypA) is thought to have numerous cellular functions, including protein folding 
through cis/trans isomerisation, immune response, lipid and protein trafficking or transcription 
regulation. Despite these attributes, this protein is known to interact with viral proteins and 
contributes to viral pathogenesis (Saphire, Bobardt et al. 1999). CypA has also been shown to 
mediate HIV-1 attachment to target cells via heparins. This interaction to heparins was revealed 
via a domain rich in basic residues similar to known heparin binding motifs. Interaction of CypA 
and heparins represents the initial step of HIV-1 attachment and is a necessary precursor to 
gp120 binding to CD4 (Saphire, Bobardt et al. 1999). 
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Amongst the 16 classes of human cyclophilin, some classes have been demonstrated to 
bind specifically to HIV-1 capsid proteins. CypA and B have been reported to bind to the HIV-1 
gag polyprotein p55gag in vitro. The association of HIV-1 virions with CypA was shown along a 
stretch of amino acid sequences in the capsid domain of p55gag (Thali, Bukovsky et al. 1994). 
This association was inhibited in a dose dependent manner by cyclosporine A (CsA) as well as 
SDZ NIM811 ([Melle-4] cyclosporine), a non-immunosuppressive analogue of CsA. However, 
the latter was shown to be ineffective against SIVMAC, a primate immunodeficiency virus 
related to HIV-1 (Thali, Bukovsky et al. 1994). The mechanism of action of SDZ NIM811 is 
clearly different from those of all other anti-HIV agents. In a cell free assay, it has been shown 
not to be an inhibitor of reverse transcriptase, protease, integrase, and it does not interfere with 
Rev or Tat function (Steinkasserer, Harrison et al. 1995). SDZ NIM811 inhibits 2-long terminal 
repeat (LTR) circle formation in a dose-dependent manner, which is indicative of nuclear 
localization of pre-integration complexes. In addition, it inhibits integration of proviral DNA into 
cellular DNA (Steinkasserer, Harrison et al. 1995).  
In addition to its association with the above mentioned viral protein, CypA has also been 
reported to interact with HIV-I viral protein R (Vpr) as well as the capsid protein both in vitro 
and in vivo (Mascarenhas and Musier-Forsyth 2009). There is a strong correlation between the 
binding of HIV-1 capsid protein and CypA and the infectivity of certain strains of HIV. The 
capsid sequence 87His-Ala-Gly-Pro-Ile-Ala92 (87HAGPIA92) encompasses the primary CypA 
binding site (Gitti, Lee et al. 1996). In contrast to the cis proline (Pro) observed in previously 
reported structures of CypA complexed with model peptides, the Pro in this peptide, Pro-90; bind 
the CypA active site in a trans conformation. In addition to the previously identified Pro-90 site 
of the capsid protein, two interaction sites between CypA and capsid protein, p24, have also been 
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reported. Both are located in the C-terminal domain of p24 around Pro-157 and Pro-224 
(Saphire, Bobardt et al. 1999). Vpr interaction was demonstrated using surface plasma resonance 
where a seven-residue motif (RHFPRIW) centered at Pro-35 was revealed for maintaining strong 
specific binding (Zander, Sherman et al. 2003).  
In addition to the above interactions with HIV-1 proteins, CypA has also been shown to 
interact with hepatitis C virus (HCV) and is a crucial factor for its replication. Their interaction is 
through domain II of nonstructural protein 5A (NS5A) (Fischer, Gallay et al. 2010). The latter is 
crucial for HCV replication as a result it constitutes a potential target for antiviral drug 
development. However, the exact interacting amino acid residues have been determined. Table 1.1 
represents the list of known viral proteins that interact with CypA. 
 
Table 1.1: An illustration of viral proteins that are known to interact with cyclophilin A. 
Interacting protein Amino acid residues Basic/ Acidi Reference 
HIV-1 capsid pro-90 Neutral  
(Zander, Sherman et al. 2003) 
HIV-1 p24 pro-90, 157, 224 Neutral  (Fitzon, Leschonsky et al. 2000) 
HIV-1 Vpr pro-35  Neutral  (Zander, Sherman et al. 2003) 
HIV-1 heparan Arg-484, 487, 585 and 588 Basic (Saphire, Bobardt et al. 1999) 
HIV-1 p55 unknown Unknown (Thali, Bukovsky et al. 1994) 
HCV NS5A unknown Unknown (Chatterji, Lim et al. 2010) 
HCV NS2 unknown Unknown (Wang and Heitman 2005) 
HCV NS5B unknown Unknown (Wang and Heitman 2005) 
SARS-N pro-310 Neutral (Luo, Luo et al. 2004) 
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1.6. CORONAVIRUS INFECTION PROCESS 
The SARS-CoV nucleocapsid protein is a major antigen in SARS and is known to form a 
ribonucleoprotein complex with genomic RNA. In addition to its structural role, it is a 
multifunctional protein involved in viral RNA replication and translation. RNA replication and 
mRNA transcription occur in virus infected cells. For the infective process to ensue the virus must 
recognize angiotensin converting enzyme (ACE)-2 receptors on the cell surface (Yeung, Yamanaka 
et al. 2006). However, group 1 CoV including HCoV-229E utilize aminopeptide N (CD13) as its 
cellular receptor (Hofmann, Simmons et al. 2006). In addition to host cell receptors, lysosomal 
cysteine proteases are required for productive infection by some viruses. The SARS-CoV, but not 
NL63, has been shown to utilize the enzymatic activity of the cysteine protease cathepsin L to 
infect ACE-2 expressing cells (Huang, Bosch et al. 2006). Therefore, if cathepsin L could be 
inhibited, SARS infection would not occur. This suggests that 2 coronaviruses that utilize the same 
receptor nonetheless enter cells through distinct mechanisms. Figure 1.2 represents a schematic 
diagram of the replication cycle of the coronavirus. 
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Figure 1.2: Schematic diagram of the replication cycle of coronavirus. 
Attachment of the virion requires recognition of ACE-2 receptors by spike 
protein on the cell membrane of a susceptible host. The virus then enters by 
means of endocytosis with concomitant release of genetic material in the 
cytoplasm. The viral RNA is then replicated followed by assembly at the 
budding compartment (adapted from 
www.iom.edu/~/media/Files/Activity%20Files/.../SARSDenison.ppt, 2005). 
 
Coronavirus attachment onto the host cell receptors is mediated by the S protein, which has the 
longest nucleotide sequence among other structural proteins. After engagement with the receptors, 
the virus fuses with host cell membrane by a fusion mechanism.  Once the virus enters the cell and 
fuse with the cellular membrane, the positive stranded coronavirus genome is released and viral 
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replication is initiated. The viral RNA then takes over the machinery of the host cell and start to 
replicate. The coronavirus genome has a 5′ methylated cap and a 3′ polyadenylated-A tail to make it 
look as much like the host RNA as possible (Zhang, Li et al. 2003). This also allows the RNA to 
attach to ribosomes for translation. During this replication process, copies of the full length 
genomic RNA and a nested set of subgenomic RNA are generated. These subgenomic mRNA 
molecules are synthesized by the viral replicase via a discontinuous transcription mechanism, in 
which a viral leader sequence, derived from the 5′ end of the genome, is added to the 5′ end of each 
subgenomic mRNA. Adjacent to the leader sequence is a transcription regulatory sequence (TRS) 
which also precedes each ORF along the genome. The TRS has been shown to act as a high affinity 
binding site for the N-protein suggesting a role for N in transcription (Zhang, Li et al. 2003). 
Although replication can take place without N protein it does so at reduced efficiency. These 
subgenomic mRNA serves as functional templates for the translation of the structural proteins. 
Once the entire replication process has ensued the viral particles assemble at the budding 
compartment where envelopment of the nucleocapsid takes place (Zhang, Li et al. 2003).  
 
1.7. AIM OF THE STUDY  
This study was designed to clone and express human cyclophilin A (CypA) for interaction with 
human coronavirus NL63 nucleocapsid proteins. Previous studies have indicated that the SARS-N 
protein exhibit direct and specific binding with CypA. Comparison of SARS-N and NL63-N protein 
by means of in silico analysis revealed that the two sequences are homologous. Therefore, it is 
reasonable to infer that HCoV NL63 N will exhibit the same interaction as SARS-N protein.  
 
 
 
 
 
  
 
 
CHAPTER 2 
In silico analysis of human coronavirus NL63 
nucleocapsid protein 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
22 
 
2.1. ABSTRACT 
Cyclophilins (Cyp) are a family of proteins that possess peptidyl-prolyl cis-trans isomerase activity 
and play a key role in the folding of proteins (Lee 2010). About 16 classes of these proteins have 
been recorded and only 3 have been extensively studied and these include CypA, CypB, and CypC. 
Cyclophilins were originally discovered for their unique interaction with cyclosporine A, an 
immunesuppressive drug (Tian, Zhao et al. 2010). CypA has been reported to be associated with 
several diseases and most commonly with severe types of carcinoma. They have been shown to be 
up-regulated in hepatocellular carcinoma but their role in pathogenesis remains obscure. Most 
recently, CypA has been revealed to interact with numerous viral proteins and of outmost 
importance to this study is the association of CypA with coronaviruses nucleocapsid protein. The 
coronavirus N proteins are basic proteins that encapsulate viral genomic RNA to form part of the 
virus structure. SARS-N protein is known to be highly antigenic and associated with several host-
cell interactions (Stohlman, Fleming et al. 1983; Hogue and Brian 1986; Zhou, Liu et al. 2008). The 
SARS-N protein has been recently shown to exhibit high binding affinity to human CypA (Luo, 
Luo et al. 2004). This study is specifically designed to critically analyze human CypA and its 
association with human coronavirus (HCoV) NL63 nucleocapsid protein by means of in silico 
examination. In silico refers to an analysis that is performed on a computer or via a computer 
simulation. A variety of computer programs have been used to analyze nucleotide as well as amino 
acid sequences of CypA, SARS-N, and NL63-N. In the genomic branch of bioinformatics, 
homology is used to predict the function of a gene. If the sequence of gene A, whose function is 
known, is homologous to the sequence of gene B, whose function is unknown, then one could infer 
that gene B may share A′s function. Using bioinformatic tools, the results of this study clearly 
indicated that there is some degree of homology between the two strains of human coronavirus. 
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Given this evidence gathered in the results it is suffice to say that NL63-N protein may exhibit the 
same interaction with CypA. 
 
2.2. INTRODUCTION 
Cyclophilins are a group of proteins that have peptidyl-proyl cis-trans isomerase activity, 
collectively known as immunophilins. They are found in both prokaryotes and eukaryotes (Wang 
and Heitman 2005). Cyclophilins seem to be structurally conserved throughout evolution 
because they have been found in mammals, plants, insects, fungi, and bacteria. All cyclophilins 
share a common domain of approximately 109 amino acids, the cyclophilin-like domain (CLD), 
surrounded by a domain unique to each member of the family that are associated with subcellular 
compartmentalization and functional specialization (Wang and Heitman 2005). They can be 
found in most cellular compartments of most tissues and encode unique functions. About 16 
classes of cyclophilins have been reported. From the 7 major cyclophilins in human, CypA is the 
first member of mammalian cyclophilins to be identified (Galat and Bua 2010). CypA plays key 
roles in several different aspects of cellular physiology including the immune response, 
transcription, mitochondrial function, cell death, and chemotaxis (Damsker, Bukrinsky et al. 
2007). In addition to these key physiological functions of CypA, it has also been reported to 
interact with viral proteins, especially caspid proteins. Literature indicates that there seems to be 
a regular pattern of CypA interaction with these viral proteins and several studies have mapped it 
around the proline (Pro) residue. However, the exact mechanism of action still needs to be 
determined in order to elucidate strategies for therapeutic intervention. Most recently, CypA has 
been reported to interact with SARS-coronavirus nucleocapsid protein (Luo, Luo et al. 2004). 
Therefore, probing the protein-protein interactions of CypA with nucleocapsid protein is of 
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outmost significance, because the foundation for discovering drugs and/or vaccines relies on 
these molecular interactions.     
Coronaviruses are single stranded positive sense RNA viruses belonging to the 
Coronavirideae family. The latter is known to possess the largest genome of all human RNA 
viruses with the genome size of approximately 27 to 32 kb and with a guanine and cytosine (GC) 
contents varying from 32 % to 43 % (Surjit, Liu et al. 2006; Feng and Gao 2007; See, Petric et al. 
2008). All coronaviruses have a similar genome organization with the characteristic gene order 5′-
replicase ORF1ab, S, E, M, N-3′, although variable numbers of additional ORFs are present in each 
subgroup of coronavirus. The gene sequences that encode conserved proteins are frequently used 
for phylogenetic analysis e.g. nucleocapsid gene. The latter is best appreciated and confirmed by 
constructing phylogenetic trees using different genes in the coronavirus genome. Amongst 
coronaviruses, the most commonly used genes for phylogenetic studies include chymotrypsin-like 
protease, Pol, helicase, spike and nucleocapsid, because these genes are present in all coronavirus 
genome and are of significant length (Wang, Li et al. 2004; Kim, Lee et al. 2006; Woo, Lau et al. 
2009). The envelope and membrane genes, although present in all coronavirus genome, are too 
short for phylogenetic studies.  
Due to the complexity of an organism, studying their genome is very challenging and so 
the bioinformatic tools have made it possible to extract useful information about the genes and 
make possible predictions about their genome as well as protein structure. In general, genes are 
complex structures that cause dynamic transformation of one substance into another during the 
whole life of an individual or even a virus. Even the static information about a particular gene is 
very difficult to comprehend. When genes are in “action”, the dynamics of the processes in which 
a single gene is involved are thousand times more complex. This is because this gene have to 
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interact with many other genes, proteins and is influenced by many environmental and 
developmental factors (van Kampen, van Schaik et al. 2000). Modeling these interactions and 
extracting meaningful patterns is a key goal of these tools. Therefore, these tools have been 
designed to broaden our understanding of biological processes.  
Genomics, proteomics, and other molecular research technologies and developments in 
information technology have developed rapidly and have combined to produce a tremendous 
amount of information within the scientific community. The distinctive part about these tools is 
that its approach focuses on developing and applying computational intensive techniques in order 
to expand our understanding of the intricate biological processes (Cai, Han et al. 2005; Hao, Chen 
et al. 2006; Negi and Braun 2009). Traditionally, viruses were characterized and classified by 
culture, electron microscopy and serological studies. Using these phenotypic methods, 
coronaviruses for example were defined as enveloped viruses of 120-160 nm in diameter with a 
crown-like appearance. The invention of nucleic acid amplification technologies, automated DNA 
sequencing and bioinformatics tools in the recent decades have revolutionized the characterization 
and classification of viruses. Bioinformatics apply the principle of information science and 
technologies to complex life science data (Wang, Ji et al. 2003; Hao, Chen et al. 2006). They have 
emerged as an important discipline within the biological science that allows scientists to decipher 
and manage the vast quantities of genomic data that is now available. Previous studies have 
reported that the ultimate goal of biological researches is to develop knowledge that will allow 
predictive approaches to all life science. In this regard, the data acquisition, management and 
analysis technique of bioinformatics are crucial as they provide a lens through which accumulated 
large-scale data set and knowledge can be viewed.  
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In this particular study, the in silico analysis has been applied in order to predict how 
human cyclophilin A (CypA) interacts with human coronavirus NL63 nucleocapsid protein. 
Mapping the interactions of CypA with the viral capsid proteins can provide clues to the initial 
infection process. Previous studies have showed the involvement of CypA in HIV-1 infection by 
demonstrating that CypA-deficient viruses could not replicate because they fail to attach to target 
cells. They demonstrated that CypA is exposed at viral membrane and mediates HIV-1 attachment. 
Therefore, a comprehensive understanding of the role of CypA in coronavirus can give some 
indication of viral pathogenesis. To gain insight into the potential role of CypA in human 
coronavirus NL63 infection, bioinformatics tools have been used to explore potential interactions 
between NL63 nucleocapsid protein and CypA. 
 
2.3. MATERIALS AND METHODS 
2.3.1. Coronavirus DNA sequence alignment 
The nucleotide sequences of the genes were extracted from the National Centre for Biotechnology 
Information (NCBI). Accession numbers for all studied genes are indicated in table 2.3. DNA 
sequences were displayed in FASTA format and were subsequently used to perform further in silico 
analysis. In order to compare the homologous nucleotide sequences of coronavirus genes, ClustalX 
version 1.81(Aiyar 2000) was used and the sequences were edited using Gendoc version 2.6.002. 
These programs provided substantial evidence pertaining to the ancestry of these viruses. Studying 
evolutionary relationship between all human coronaviruses was achieved by sequence alignment. 
100 % homology between these sequences is indicative of conserved regions and these are 
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described on each as follow:  100 % homology,  > 60 %,  < 50 % and white indicates 0 % 
homology .  
 
2.3.2. Coronavirus amino acid sequence alignment 
The primary structures of the proteins were obtained using Expasy 
(http://web.expasy.org/translate/), which directly transcribed and then translated DNA into amino 
acid sequence. From the list of amino acid sequences the desirable sequence was chosen by virtue 
of having the least number of stop codons. The homologous sequences between these amino acid 
sequences were also compared using ClustalX. Conserved motifs amongst coronavirus 
nucleocapsid proteins were conducted by aligning sequences. Furthermore, the viral proteins known 
to interact with CypA were also aligned in order to predict potential motifs for protein-protein 
interaction.  
 
2.3.3. Prediction of nuclear localization signals 
The relationship between the different strains of human coronavirus was also studied by comparing 
their nuclear localization signals, nuclear export signals and their motifs that are involved with 
interaction of the N protein with host protein and with itself. The nuclear signals were carried out 
using the PSORT analysis program (http://psort.hgc.jp/form.html) whereas the motif scan was 
performed using Prosite tools. A motif scan with sufficient information on O-glycosylation and 
phosphorylation sites was retrieved by means of MOTIF-SCAN (http://hits.isb-sib.ch/cgi-
bin/PFSCAN). The program also supplies valuable information about the possible sites that exhibit 
potential phosphorylation and O-glycosylation sites.   
 
 
 
 
Chapter 2 
 
28 
 
2.3.4. Prediction of cyclophilin A interacting site 
All proteins that are known to interact with CypA were retrieved from published literature. These 
proteins are shown in table 2.1 and their amino acid sequences were obtained from published 
material. Homologous sequences were compared using ClustalX. From the sequences, the potential 
motifs were searched manually by comparing homologous sequences. Moreover, the homologous 
sequences or amino acid residues were compared in terms of their functional groups in order to 
predict how these proteins interact with CypA.  
 
Table 2.1: An illustration of viral proteins that are known to interact with cyclophilin A. 
Interacting protein Amino acid residues Basic/ Acidic Reference 
HIV-1 capsid pro-90 Neutral  
(Zander, Sherman et al. 2003) 
HIV-1 p24 pro-90, 157, 224 Neutral  (Fitzon, Leschonsky et al. 2000) 
HIV-1 Vpr pro-35  Neutral  (Zander, Sherman et al. 2003) 
HIV-1 heparan Arg-484, 487, 585 and 588 Basic (Saphire, Bobardt et al. 1999) 
HIV-1 p55 unknown Unknown (Thali, Bukovsky et al. 1994) 
HCV NS5A unknown Unknown (Chatterji, Lim et al. 2010) 
HCV NS2 unknown Unknown (Wang and Heitman 2005) 
HCV NS5B unknown Unknown (Wang and Heitman 2005) 
SARS-N pro-310 Neutral (Luo, Luo et al. 2004) 
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2.4. RESULTS 
2.4.1. Multiple sequence alignment  
The full length genes for all genes were successfully retrieved from NCBI. On the appendices 
(Appendix 2, page 120-134), the nucleotide and amino acid sequences of these genes are illustrated. 
Initially, the evolutionary relationship between all human coronaviruses was performed by aligning 
DNA sequence. In figure 2.1 it is noticeable that these viruses share a common ancestry. The 
conserved nucleotide sequences are indicated by dark regions and the significance of this 
relationship is described on each figure. Furthermore, the bovine coronavirus seems to be more 
homologous with OC43, whereas the rest of the viruses have relatively fair amount of homology.  
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Figure 2.1: Comparison of homologous nucleotide sequences between the different strains 
of all human coronaviruses. The dark regions indicate some of the conserved regions 
within the Coronavirideae family. 
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Following the alignment of DNA sequences, this relationship was further compared by aligning 
amino acid sequences. From figure 2.2, it is clear that different strains expressing N proteins exhibit 
some degree of variation. It is interesting to note that there are multiple stretches of amino acid 
residues that share 100 % homology and this is shown in figure 2.2. Moreover, the length of these 
homologous amino acids is relatively longer in comparison to DNA sequence alignments.  
 
Figure 2.2: Comparison of homologous protein sequences between the different strains of 
all human coronaviruses. The dark regions indicate some of the conserved regions within 
the Coronavirideae family. 
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To gain insight into the HCoV-N protein motifs that could potentially interact with CypA, sequence 
alignment between SARS-N and NL63-N was done. The literature indicates that SARS-N interacts 
along a specific stretch of amino acid residues (Trp302-Pro310), therefore this region was searched 
manually and homology determined. In figure 2.3, this region is labeled as “A” and it is clear that 
there is high degree of homology along these amino acid residues.  
 
Figure 2.3: Illustration of homologous amino acid sequences between SARS and NL63 
nucleocapsid proteins. The dark regions indicate some of the conserved regions within 
the Coronavirideae family. “A” indicates the SARS-N motif that is known to interact 
with CypA.  
 
Although the two sequences present with conserved residues, there are some notable variations. 
SARS-N amino acid sequence appears to be longer than NL63-N with amino acid residues of 422 
and 377, respectively. In addition, SARS-N protein presents with a larger molecular weight when 
compared to NL63-N protein. These differences are indicated in table 2.2.  
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Table 2.2: Comparison of SARS-N protein molecular weight and amino acid sequence to NL63-N protein. 
Gene Molecular weight (kDa) Amino acid residues 
NL63-N 42.26 377 
SARS-N 46.04 422 
 
2.4.2. Prediction of nuclear localization signals 
The classical nuclear localization signals (NLS) include sequence regions that are rich in basic 
amino acids and generally conform to one of three types: Pat4, Pat7 and Bipartite motif. “Pat4” 
NLS consist of a continuous stretch of four amino acids (lysine or arginine) or three basic amino 
acids associated with histidine or proline. “Pat7”, on the other hand, starts with a proline followed 
within three residues by a segment containing three basic residues. Lastly, bipartite consist of two 
basic amino acids, a 10 amino acid space, and a five amino acid segment containing at least three 
basic residues.   
It is noticeable that all coronaviruses studied possess the “Pat7” localization signal with the 
exception of feline coronavirus. It is also appreciable that amongst human coronaviruses, only the 
recently discovered (SARS and NL63) possess “Pat4” localization signal. In addition, the results 
reveal that in all human coronaviruses, only SARS has bipartite localization signals. These NLS are 
crucial in the translocation of nuclear proteins i.e. N proteins that localize in the nucleus, from the 
cytoplasm, across the nuclear pore complex into the nucleus. From table 2.3 it is clear that amongst 
all coronaviruses there are distinctions in localization signals. 
 
 
 
 
 
Chapter 2 
 
34 
 
Table 2.3: Prediction of NLS for N-protein within mammalian coronaviruses using PSORT analysis.  
  Group 1 HCoV   
  GenBank Pat4 Pat7 Bipartite 
Feline CoV NC_007025.1 None None 326- KRPSEVAKDQRQRRSRS 
HCoV 229E NC_002645.1 None 45-PINKKDK None 
    198-PQEKDKK   
    247-PRWKRQP   
TGEV AY587884.1 5-RKRK  None  199-KKLGVDTEKQQQRSRSK 
    Group 2 HCoV     
  GenBank Pat4 Pat7 Bipartite 
PHEV NC_007732.1  None 270-PRQKRSP None 
Bovine Coronavirus  EF424619.1 None  269-PRQKRSP None 
Murine hepatits virus NC_001846.1 None  271-PRQKRTP None 
    392-PQRKGRR   
Human CoV OC43 NC_005147.1 None  270-PRQKRSP None  
SARS-CoV NC_004718.  257-KKPR 38-PKQRRPQ 373-KKKKTDEAQPLPQRQKK 
   373-KKKK 259-PRQKRTA 374-KKKTDEAQPLPQRQKKQ 
    369-PKKDKKK   
    384-PQRQKKQ   
HCoV NL63   232-KKPR 234-PRWKRVP None 
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2.4.3. Motif scan 
Motif scan of the CypA, SARS and NL63 nucleocapsid protein revealed the following. In table 2.5 
the NL63-N protein has only one O-glycosylation sites at the threonine residue. Interestingly, the 
SARS-N protein also exhibits one glycosylation sites at the same amino acid residue. The NL63 
and SARS-N protein also exhibit the same kind of properties when analyzing their O-glycosylation 
sites on the tyrosine and the serine residues. Therefore, SARS-N appears to possess the same O-
glycosylation properties as the NL63-N protein. Predictions of the CypA, on the other hand, do not 
have any O-glycosylation sites. With regards to phosphorylation sites, as indicated in table 2.4, 
there is also a notable variation in terms of amino acid residues. The two proteins appear to have 
more phosphorylation sites at the serine residue and then followed by threonine residues. In table 
2.4 it is clearly shown that tyrosine residues exhibit the least number of phosphorylation sites. 
Moreover, the CypA seems to possess the least number of phosphorylation sites.  
 
Table 2.4: The prediction of phosphorylation sites using NetPhos. 
Protein Serine Threonine Tyrosine 
CypA 4 1 0 
SARS-N 22 8 3 
NL63-N 29 3 2 
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Table 2.5: The prediction of O-glycosylation sites using NetGlo. 
Protein Serine Threonine Tyrosine 
CypA 0 0 0 
SARS-N 1 1 0 
NL63-N 1 1 0 
 
2.4.4. Prediction of interacting sites 
The potential sites of interaction for HCoV NL63-N were predicted by comparing sequences of all 
proteins known to interact with CypA. From the published literature, these sites seem to be centered 
on the proline residue. However, in SARS-N protein, the mapped site does not involve proline. 
Whereas the amino acid residues of other proteins seem to be of a consistent functional group, the 
SARS-N site belongs in multiple functional groups. In figure 2.4, it is noticeable that SARS-N does 
not share homology with other viral proteins known to interact with CypA.  
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Figure 2.4: Illustration of homologous amino acid sequences between proteins that are 
known to interact with CypA.  
 
2.5. DISCUSSION   
2.5.1. Homologous DNA sequences  
The primary purpose of analyzing nucleotide sequences is to increase our understanding of the 
biology of newly emerging microorganisms. This study was specifically designed to compare 
SARS-N and NL63-N protein. Research has showed that SARS-N protein interacts with CypA. The 
results of this study clearly indicate that there is some degree of homology between the two 
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coronavirus sequences. Therefore, it is suffice to say that NL63-N protein may exhibit the same 
characteristics as the SARS-N protein. This is attributed to the fact that comparing sequences with 
known function i.e. the SARS-N protein, with the new sequence i.e. NL63-N protein, enables us to 
make reasonable inferences about the biology of the new sequence. Thus, sequence analysis helps 
the scientific community to compare sequences to find both similarities and differences between 
compared sequences.  
 
2.5.2. DNA guanine-cytosine (GC) content:   
The GC content represents the percentage of guanine and cytosine nitrogenous bases on a DNA 
molecule (Woo, Lau et al. 2005; Mills 2006). This parameter is looked at in order to understand the 
stability of the DNA molecule because it is believed that a high GC content is associated with more 
stable DNA whereas a low GC content is associated with less stable DNA (Woo, Lau et al. 2005). 
However, this popular belief remains controversial. Nevertheless, the difference in GC content 
between the two species is relatively insignificant. Therefore, for the purpose of this study the 
difference in GC content is negligible.  
The study results show that the SARS-N gene has more GC than NL63. This could be 
attributed to the fact that the length of the coding sequence is directly proportional to the GC 
content (Woo, Lau et al. 2005). Also the bias of the stop codon towards the adenine (A) and 
thymidine (T) nucleotides may contribute to the high GC content (Woo, Lau et al. 2005).  
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2.5.3. Amino acid sequence 
The structural modifications that occur in proteins either during their synthesis or after translation 
are imperative in understanding the intricate biological processes that occur within the cell. These 
modifications may either activate proteins or render them inactive. This study proves that there are 
some post-translational modifications that occur in our proteins of interest. They may undergo 
glycosylation, phosphorylation or myristilation and other post-translational modification that are 
implicated in protein structure and function. For the purpose of this study, focus is drawn onto the 
above mentioned processes.  
The process of glycosylation occurs in the cytoplasm and nucleus (Ying, Hao et al. 2004; 
Han, Lohani et al. 2007). However, O-glycosylation that is implicated in these proteins occurs in 
the Golgi apparatus and is catalyzed by the enzyme UDP-N-acetyl-D-galactosamine: polypeptide 
N-acetylgalactosamine transferase (Ko, Kang et al. 2006). The SARS-N and NL63-N protein seem 
to be glycosylated at the serine and threonine residues. This process occurs by attachment of O-
linked glycan to the hydroxyl oxygen of serine and threonine side chains (Shih, Chen et al. 2006). 
These glycans appear to serve various functions viz. protein folding and stability. Literature 
indicates that linking of these glycans to target proteins confer some stability to the protein.  
Phosphorylation, on the other hand, occurs on serine, threonine and tyrosine residues in 
eukaryotic cells. Phosphorylation replaces neutral hydroxyl groups on serines, threonines, or 
tyrosines with negatively charged phosphates (Wang, Ji et al. 2003; Mizutani, Fukushi et al. 2004; 
Zeng, Ruan et al. 2004). Research shows that serine is the most commonly phosphorylated amino 
acid, followed by threonine and then tyrosine. This is in agreement with the results of this study. 
The phosphorylation process is crucial, because, of its ability to effectively turn a hydrophobic 
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portion of a protein into a polar and extremely hydrophilic portion. This is of particular interest to 
scientists, because this process may confer antigenic properties to the target protein i.e. SARS-N 
or/and NL63-N protein.  
 
2.5.4. Analysis of protein interaction using bioinformatics 
Protein interactions using bioinformatic tools provide valuable information about the potential 
interacting site. The probable binding site for HCoV NL63-N protein was determined by 
comparing the SARS-N interacting domain with NL63-N. However, this site is remarkably 
different when compared to other viral proteins known to interact with CypA. Therefore, it is 
suffice to say that the coronavirus N proteins have a unique binding mode to this protein, CypA. 
Alternatively, CypA might have multiple stereochemically active sites that enable it to interact 
with these proteins.  
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3.1. ABSTRACT 
The Coronaviridae family is composed of a number of ribonucleic acid (RNA)-containing viruses 
currently classified into two genera, the coronavirus and torovirus. The family is classified together 
with the Arteviridae in the order Nidovirales. Coronaviruses are enveloped single stranded positive 
sense RNA viruses about 80-160 nm in diameter. The coronavirus is a positive sense RNA virus 
and the naked RNA is infectious. The 5′-two thirds of the genome encodes for a polyprotein that 
contains all the enzymes necessary for replication, whereas the 3′-one third encodes for all the 
structural proteins that mediate viral entry into the host cell. The structural proteins include spike 
(S), envelope (E), membrane (M) and nucleocapsid (N) proteins. 
N is one of the most crucial structural components of coronaviruses; hence major attention 
has been focused on characterization of this protein. Some laboratories have demonstrated that this 
protein interferes with different cellular pathways, thus implying it to be a key regulatory 
component of the virus (Zakhartchouk, Viswanathan et al. 2005). Furthermore, it has been shown 
that severe acute respiratory syndrome (SARS)-N protein interacts with cellular proteins, including 
cyclophilin A (CypA), heterogenous nuclear ribonucleoprotein (hnRNP) A1, human ubiquitin-
conjugating enzyme, cyclin dependent kinase (CDK)-cyclin complex protein, Ikappaßalpha (IkBα), 
cytochrome (Cyt) P450 etc. For the purpose of this study, the focus is based on CypA interaction 
with the human coronavirus (HCoV) NL63 N protein. These interactions might play a role in the 
pathology of HCoV-NL63. Since the N protein is involved in viral RNA packaging to form a 
helical core, it is suffice to say that both NL63-N and CypA are possibly within the HCoV-NL63 
replication/transcription complex and NL63-N/human CypA interaction might function in the 
regulation of HCoV-NL63 RNA synthesis. In this chapter, total RNA was extracted from a human 
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cell line (MCF7) and used to generate first strand cDNA. This was used to amplify human CypA 
with specific primers for subsequent cloning into a vector and expression of the protein in a 
bacterial system. Human CypA was expressed, purified and quantified for future studies.    
 
3.2. INTRODUCTION  
Cyclophilins are a group of proteins that have peptidyl-proyl cis-trans isomerase activity, 
collectively known as immunophilins. Human CypA has previously been shown to exhibit high 
binding affinity to the SARS-coronavirus N protein. This interaction occurs via Trp 302-Pro 310 
loop (Luo, Luo et al. 2004). However, the significance of this interaction has not been established. 
CypA is a peptidyl-prolyl cis/trans isomerase (PPIase) that is involved in multiple signaling events 
of eukaryotic cells. CypA catalyses the cis/trans isomerisation of proline imide bonds in peptides. 
They were initially identified as immune modulators through their binding to cyclosporin A (CsA), 
an immunosuppressant (Daum, Schumann et al. 2009; Chatterji, Lim et al. 2010; Fischer, Gallay et 
al. 2010; de Wilde, Zevenhoven-Dobbe et al. 2011). The human genome encodes up to 16 different 
cyclophilins. Despite their differences in tissue distribution, sub-cellular localization and relative 
abundance, they all share a similar 3-D structure and show in vitro PPIAse activity (Zheng, 
Koblinski et al. 2008; Daum, Schumann et al. 2009; Han, Yoon et al. 2010). In vivo, they are 
thought to have numerous cellular functions, including protein folding through cis/trans 
isomerisation, immune response, lipid and protein trafficking or transcription. Most amino acids 
have a strong energetic preference for the trans peptide conformation, therefore the cis/trans 
activity of CypA is crucial for the stabilization of the cis conformation. 
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Studies have shown that CypA is a potential target for antiretroviral therapy. This is based on the 
fact that inhibition of CypA was shown to suppress human immune virus (HIV)-1 replication but 
the mechanism remains unclear. CypA interacts with HIV-1 viral protein R (Vpr) both in vitro and 
in vivo (Zander, Sherman et al. 2003; Hatziioannou, Perez-Caballero et al. 2005; Javanbakht, Diaz-
Griffero et al. 2007). Moreover, these interactions occur on the N-terminal regions of CypA 
containing Pro-35, and surface plasmon resonance studies revealed that a seven residue motif 
centered at Pro-35 consisting of RHFPRIW is sufficient for maintaining strong specific binding 
(Zander, Sherman et al. 2003; Javanbakht, Diaz-Griffero et al. 2007). Previous studies have also 
concluded that the ability of CypA to interact with N-terminal Vpr peptides is determined by Pro-
35. There is convincing evidence that CypA only binds specifically to peptides containing the seven 
residue motif RHFPRIW centered at Pro-35 of the N-terminal Vpr (Solbak, Reksten et al. 2010). 
This region includes the loop region connecting helices 1 and 2 of Vpr, in addition to the Arg-32 
and His-33 that terminate the well-defined helix 1 and 2 (Solbak, Reksten et al. 2010). The study 
revealed that the structural data for N-terminal mutant of Vpr in which Pro-35 is exchanged for Asn 
indicates a merge of helices 1 and 2 meaning interaction with CypA disrupts the hydrophobic 
interaction of the two helices. FGPDLPAGP has been shown to be an active site inhibitor for CypA, 
and nuclear magnetic resonance studies have showed that there is some overlap between the 
binding epitope and CsA drugs. In human proteins, the linear sequence recognition code was found 
to be consensus sequence FGPXlp. However, the peptide FGPDLPAG shows inhibition of the 
CypA isomerase reaction highlighting CypA interaction epitope (Fischer, Gallay et al. 2010). 
In addition to Vpr interaction, CypA also interacts with HIV-1 capsid protein. CypA is a 
highly conserved peptidyl prolyl cis/trans isomerase (PPIA) that is incorporated into HIV-1 virions 
and play a role in the early stages of viral replication (Khan, Garcia-Barrio et al. 2003; Javanbakht, 
 
 
 
 
Cloning and expression of CypA 
45 
 
Diaz-Griffero et al. 2007; Mascarenhas and Musier-Forsyth 2009). The HIV-1 capsid interacting 
region with CypA encompasses nine residues 85-93 (PVHAGPIAP) belonging to a loop region 
connecting helices 4 and 5, respectively, of HIV-1 capsid (Li, Tang et al. 2007). Gly-90 and Pro-90 
on HIV-1 capsid protein were shown to be the most crucial amino acid targets of CypA binding. 
Hatziiaoanou et al. (2005) reported that CypA acts as a chaperone with Pro-90 of N-terminal HIV-1 
capsid peptide (residues 1-151). The binding of CypA with HIV-1 capsid protein positively affects 
some early stages of the viral life cycle (Li, Tang et al. 2007). This is because prevention of viral 
binding either by drugs that occupy that active site of CypA, by mutation in HIV-1 capsid protein, 
or RNAi that knocks down intracellular CypA levels diminishes viral infectivity. Therefore it′s 
sufficed to say that viral infectivity is improved by high levels of CypA. CsA is known to exhibit 
the same binding activity in a loop between the 4th and 5th helices of the capsid protein, and 
disrupts the CypA-capsid interaction, which leads to attenuation of HIV-1 (Keckesova, Ylinen et al. 
2006; Noser, Towers et al. 2006).  Literature indicates that there is also a strong correlation between 
the binding of HIV-1 capsid protein and CypA and the infectivity of certain strains of HIV. In 
addition to HIV-1, CypA also interacts with other closely related lentivirus such as feline 
immunodeficiency virus (FIV) and samian immunodeficiency virus (SIV) proteins. The interaction 
of CypA is more widespread amongst lentivirus (Qi, Yang et al. 2008; Takeuchi 2010). 
CsA has been reported to exert anti hepatitis C virus (HCV) activity in vitro and in vivo and 
is a crucial factor for HCV replication. Some studies have revealed that even CypB and CypC are 
indispensible for HCV replication and this interaction is through domain II of nonstructural protein 
5A (NS5A) (Hatziioannou, Perez-Caballero et al. 2005; Chatterji, Lim et al. 2010). NS5A is crucial 
for HCV replication as a result it constitutes a potential target for antiviral drug development. 
DEB025, a CypA inhibitor, interferes with the interaction between CypA and NS5A, thereby 
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inhibiting HCV replication. DEB025 sequesters CypA and therefore prevent conformational 
changes in the replication complex that are crucial for viral replication (Chatterji, Lim et al. 2010). 
This unique feature makes it by far a more efficient drug than “classical” direct acting antivirals 
(DAA) inhibitors. Fischer et al. (2010) revealed that interaction of NS5A with CypA is completely 
abolished in the presence of CsA.  Studies have shown that a combination of CsA and DEB025 
inhibits the CypA-NS5A interaction in a dose dependent manner. Furthermore, DEB025 was shown 
to be more potent than CsA meaning that the affinity of DEB025 to CypA is more superior to that 
of CsA. 
 
3.3. MATERIALS AND METHODS 
3.3.1. Reagents 
MCF7 cells were obtained from the Experimental Biology Group (University of the Western Cape, 
Department of Medical Biosciences). HCoV-NL63 RNA (a kind gift from Prof. L van der Hoek, 
Holland) was extracted from a fifth-passage virus (strain Amsterdam 1) obtained from a clinical 
sample. SDS gel preparation kit, DMSO, BAP-FLAG and Anti-FLAG M2 antibodies were 
purchased from Sigma Aldrich. Goat polyclonal Anti-Mouse IgG (H&L) was purchased from 
Koma Biotech. All other chemicals were purchased from Promega.  
 
3.3.2. Tissue culture 
MCF7 cells were grown and maintained as monolayers in 75 cm
2
 tissue culture flasks. These cells 
were cultured in Dulbecco′s modified eagle medium (DMEM) supplemented with 10 % fetal bovine 
serum (FBS) and 1 % filtered antibiotic mix containing Penicillin (100 U), Streptomycin (0.1 
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mg/ml), and Amphotericin B (10 U). The flasks were then incubated at 37 
o
C in a humidified 
incubator with a constant supply of 5 % CO2. The cell monolayers were passaged each time they 
reached approximately 90 % confluency as confirmed by light microscopy. Once confluent, the 
MCF7 cells were first washed with sterile 1 x phosphate buffered saline (PBS), followed by 
treatment with Trypsin-Versene (EDTA) (Gibco) for approximately 2 min with gentle shaking. 
Once the cells detached from the surface, they were diluted with fresh medium and then seeded into 
fresh 75 cm
2
 flasks. The cells were subcultured for a minimum of three passages and then harvested 
if there was no contamination after three successive subcultures. The latter involved treating 
confluent cells with Trypsin-Versene (EDTA) for 2 min followed by addition of fresh medium, 
vigorous pippeting and then incubation at room temperature for 5 min. Detached cells were then 
transferred to a 15 ml Greiner tube and centrifuged for 5 min at 3 000 rpm at 4
o
C.  The supernatant 
was discarded and the pellet kept for RNA extraction.                                                                                
 
3.3.3. Bacterial strains and plasmids 
All bacterial strains used in this study were purchased from Promega and they include KRX, BL21 
and JM109 competent cells. KRX is an E. coli K12 derivative that has most important features 
associated with cloning and screening strains. BL21, on the other hand, is a λ (DE3) pLysS strain 
that can be used with protein expression vectors that are under the control of the T7 promoter. For 
initial transformation of the recombinant vector, JM109 competent cells were used, whereas KRX 
and BL21 competent cells were used for optimization and final expression of recombinant protein. 
The plasmid vectors used were pGEM-T EastVector system II and pFN2A (GST) Flexi vector. The 
Flexi vector was used because of its unique ability to express fusion or native proteins in order to 
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study protein structure and function as well as interactions. In contrast, pGEM vector was utilized 
because of its convenience for cloning of PCR products.  
 
3.3.4. Generation of recombinant plasmid vectors 
3.3.4.1. Design of PCR primers 
The human CypA nucleotide sequence was retrieved from NCBI. Using the obtained nucleotide 
sequence as a template, the forward and reverse primers were designed using Promega primer 
design tools. For ligation into the Flexi™ protein expression vector a SgfI (5´-GCGATCGC-3´) 
restriction-site was incorporated into the forward primer and a PmeI (5´-GTTTAAAC-3´) 
restriction site was incorporated into the reverse primer. An additional C residue was appended 
upstream of the ATG in the forward sequence to prevent a frameshift in the reading frame. 
Porphobilinogene deaminase (PBDG) was used as PCR internal control and primers were donated 
by the Breast Cancer Research Group (University of the Western Cape, Department of Medical 
Biosciences). These primers were used as 100 ρ.mole/μl stock solutions and their nucleotide 
sequences are shown in table 3.1.   
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Table 3.1: Primers used for the amplification of human CypA and PBDG. 
Gene Primer Primer sequence 
Human CypA Forward AGGAGCGATCATGGCAGTGGCAGAAGATTTTAA 
 Reverse TTGTGTTTAACGTCATCGATACCGTCACCGTCTTCTAAAATTCAAATTTG 
PBDG Forward TCCTGCACCCTGAGGAAT 
 Reverse CCTCAGGAAGGCCCTTT 
Sgf1 restriction site- underlined 
Pme1 restriction site- italics 
 
3.3.4.2. Amplification of full length human cyclophilin A gene 
Total cellular RNA was extracted from MCF7 cells using the Trizol method. Briefly, the cells 
were lysed by addition of Trizol reagent to the cell pellet, which was then homogenized by 
pippeting several times. The tube was then incubated at room temperature for 5 min with 
occasional pippeting. The sample was then treated with chloroform, mixed gently by inverting 
for 5 min, and then centrifuged at 3 000 rpm for 10 min. Following spin down, the supernatant 
was aspirated to a new tube and then washed with isopropanol. This was then incubated at for 10 
min at room temperature, followed by centrifugation at 3 000 rpm for 10 min. The supernatant 
was discarded, while the pellet was washed three times with 70 % ethanol. The latter was air 
dried and the pellet re-dissolved in nuclease free water. Reverse transcription was done in a 
mixture of 1 µl RNA template (108-109 copies/ml), 1 µl of Oligo (dT)15 primer (100 µM stock), 
1× incubation  buffer, 2 µl of dNTP mix (10 mM stock), 20 U RNasin
®
 Ribonuclease inhibitor, 
15 U of AMV Reverse Transcriptase and 4 µl MgCl2 (25 mM) in a total volume of 20 µl in 
nuclease-free water, according to the manufacturer’s specifications (Promega). The reaction was 
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heated at 42 ºC for 60 min, 95 ºC for 5 min and then cooled to 0 ºC for 5 min to deactivate the 
enzyme. Next the gene was amplified by means of polymerase chain reaction (PCR). CypA was 
amplified from the cDNA library of MCF7 cells using gene specific primers. In table 3.2 the 
PCR conditions were designed in such a way that the annealing temperature for the reaction is 5 
o
C lower than the melting temperature of the forward primer and the reverse primer. These 
amplification reaction mixtures are shown in table 3.2.  
 
Table 3.2: Polymerase chain reaction (PCR). 
Reagent  Negative control (µl) Internal control (µl) Human CypA (µl) 
cDNA 0 2 2 
dNTP 0.5 0.5 0.5 
MgCl2 1.5 1.5 1.5 
5X Mg free buffer 10 10 10 
Forward primer 1 1 1 
Reverse primer 1 1 1 
Go Taq 0.5 0.5 0.5 
Nuclease free water to final volume of 50 
 
PCR amplification reactions were run under the following conditions: 95 °C for 3 min followed 
by 30 cycles of 95 °C for 1 min, 50 °C for 1 min and 72 °C for 1 min. The final elongation was 
run for 15 min at 72 °C. The PCR product was diluted in a ratio of 1:6 with 6 x Blue/Orange 
loading dye (0.4 % (v/v) orange G, 0.03 % (v/v) bromophenol blue, 0.03 % (v/v) xylene cyanol 
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FF, 15 % (v/v)  Ficoll® 400, 10 mM Tris-HCl (pH 7.5) and 50 mM EDTA (pH 8.0)) The 
amplification reactions were run on a 1 % (w/v) agarose gel, containing 0.001 % (v/v) ethidium 
bromide, by electrophoresis in TBE buffer (89 mM tris (hydroxymethyl) aminomethane, 0.089 
mM boric acid, 2 mM EDTA (pH 8)). The gel was run at 90 volts, 2 amperes for a period of 
approximately 1 hour. The size of the DNA fragment of interest was determined according to the 
DNA migration pattern in an agarose gel compared to that of a pre-determined DNA molecular 
weight marker. When the PCR fragment was visualized under the high frequency ultraviolet 
(UV) light, exposure to UV light was minimized to avoid damage to the DNA. The PCR product 
to be ligated was gel purified by means of the Wizard® PCR Preps DNA purification systems 
(Promega) according to the manufacturer′s specifications. Briefly, the bands to be cloned were 
excised from the agarose gel by means of a clean scalpel and razor blade. A weighed gel slice 
was completely dissolved by incubation at 50 
o
C for 10 min with occasional vortexing in the 
presence of a membrane binding solution (4.5 M guanidine isothiocyanate and 0.5 M potassium 
acetate) at a ratio of 1:1. The gel mixture was then transferred into an SV minicolumn, where it 
was washed with membrane wash solution (10 mM potassium acetate, 80 % (v/v) ethanol and 
16.7 μM EDTA). The DNA was finally eluted with nuclease-free water into a sterile micro-
centrifuge tube. 
 
3.3.4.3. Cloning and verification of amplification products 
3.3.4.3.1. Cloning of amplification product  
The product that was purified using Wizard® PCR Preps DNA purification systems was then 
prepared for ligation into an expression vector. Following PCR product preparation, the amplicon 
was cloned into pGEM-T easy vector according to the standard specifications of Promega manual 
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followed by transformation into JM109 competent cells. Table 3.3 represents the ligation reaction 
that was followed according to Promega standards.  
 
Table 3.3: Ligation into pGEM vector. 
Reagent  Positive control (µl) Background control (µl) pGEM reaction (µl) 
2X rapid ligation buffer 5 5 5 
pGEM-T vector (50ng) 1 1 1 
PCR product 0 0 2 
Control insert DNA 2 0 0 
T4 DNA ligase 1 1 1 
 
Following the ligation reaction that is represented in table 3.3, the ligation product was transformed 
into JM109 competent cells. This involved placing competent cells that were frozen at -80 
o
C on ice 
for 5 min until thawed. The DNA to be transformed was pippeted to the bottom of the tube with 50 
µl competent cells and incubated on ice for 10 min. This was followed by a heat shock step 
whereby the sample was incubated in a 42 
o
C water bath for 40 sec and then immediately returned 
to ice for 2 min. The cells were then transferred to 1 ml of pre-warmed Luria Bertani (LB) broth (10 
g pancreatic digest of casein, 5 g yeast extract powder and 5 g NaCl per 1litre water), containing no 
antibiotics. The mixture was incubated at 37 
o
C for 1 hour with shaking at 300 rpm. The cells were 
then plated on LB-agar selective plates supplemented with ampicillin (100 mg/ml), (Isopropyl-ß-D-
thio-galactoside) IPTG (100 mM), and X-gal (3 %). These plates were incubated overnight (12-16 
hours) at 37 
o
C. 
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The efficiency of transformation was measured using the following standards: Typically, 
approximately 100 colonies should be observed (according to Promega′s standards) - 10-30 % of 
which are blue when competent cells that have a transformation efficiency of 1 x 10
8
 cfu/μg DNA 
are used. Greater than 60 % of the colonies should be white, which is indicative of efficient 
transformation. If less than 50 % of the white colonies are seen in the positive control reaction, this 
was regarded as indicative of suboptimal conditions. Cells that were successfully transformed were 
selected using Blue/White colony selection, where transformants were subjected to colony PCR to 
verify the presence of the construct before it can be isolated. Briefly, colony PCR involves selecting 
multiple colonies from a spread plate and mixing with PCR reagents as described in table 3.2. 
These colonies are inoculated into 15 ml LB broth supplemented with ampicillin and grown 
overnight. Once the PCR products have been confirmed in agarose gel electrophoresis, the cultures 
that correspond to the correct genes are selected for plasmid DNA isolation using Wizard® plus SV 
minipreps DNA purification system.   
 
3.3.4.3.2. Plasmid DNA extraction 
Plasmid DNA was isolated from the transformed cells using Wizard® plus SV minipreps DNA 
purification system. Briefly, a single bacterial colony that was confirmed to contain the amplicon by 
colony PCR was inoculated into 10 ml of LB medium containing antibiotics and incubated 
overnight at 37 
o
C. The culture was pelleted for 5 min and then immediately resuspended in 250 µl 
of cell re-suspension solution (50 mM Tris-HCl, 10 mM EDTA). This was mixed with another 250 
µl of cell lysis solution (1 % (w/v) SDS, 0.2 M NaOH) and then mixed by inverting. To this 
mixture, 10 µl of alkaline protease solution was added, mixed and then incubated for 5 min at room 
temperature. Following incubation, the sample was mixed with 350 µl of neutralizing solution (80 
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mM potassium acetate, 8.3 mM Tris-HCl, 40 μM EDTA), inverted and then centrifuged at top 
speed (13 000 rpm) at room temperature for 10 min. Once the cleared lysate was obtained, the 
lysate was decanted into a spin column and then centrifuged for 1 min at top speed. Flow through 
was discarded and the column reinserted into the collection tube. 750 µl of wash solution was added 
and the sample was centrifuged at top speed for 1 min. The spin column was then washed with 250 
µl of wash solution and centrifuged for 2 min. The plasmid DNA was eluted by transferring the spin 
column into a sterile centrifuge tube followed by addition of 30 µl of nuclease free water to the spin 
column. The latter was centrifuged at top speed for 1 min and the DNA stored at -20 
o
C.   
 
3.3.4.3.3. Restriction endonuclease digestion  
To confirm the presence of the exact protein coding region, the purified plasmid was digested with 
restriction enzyme, EcoR1, as shown in table 3.4 to verify the presence of insert.  
 
Table 3.4: Recombinant pGEM-CypA construct restriction enzyme digests. 
Reagent  pGEM enzyme digest reaction (µl) 
DNA 5 
Buffer H 2 
EcoR1 0.3 
BSA 0.4 
Nuclease free water 12.6 
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3.3.4.3.4. Nucleotide sequencing and sequence analysis  
Since PCR was used to create the original insert, the sequence of the protein coding region in the 
initial clone was verified by automated DNA sequencing. Cycle sequencing was performed at 
Inqaba Biotech. The clone corresponding to the initial nucleotide sequence (NCBI) was selected for 
further experimentation. Following in silico analysis, the construct was digested with pFlexi 
restriction enzymes (Sgf1 and Pme1) for ligation into pFlexi vector that has been digested with the 
same restriction enzymes. This reaction is shown in table 3.5.  Subsequent to gel purification of the 
digested product, a ligation reaction was performed whereby the protein coding region was inserted 
into a bacterial expression vector, pFlexi. The manufacture′s standard conditions for successful 
ligation of the DNA fragment are represented in table 3.6. 
 
Table 3.5: pFlexi restriction enzyme digests. 
Reagent  pFlexi enzyme digest reaction (µl) 
5X Flexi digest buffer  2 
DNA constructs  10 
Sgf 1and PmeI enzyme blend 2 
Nuclease free water 4 
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Table 3.6: Ligation into pFlexi vector. 
Reagent  Background control (µl) pFlexi reaction (µl) 
10X Flexi ligation buffer 2 2 
Flexi vector (cut with Sgf and Pme1)  5 5 
T4 ligase 1 1 
Cut DNA product 0 12 
 
Successful ligation of the DNA fragment was confirmed by digesting an aliquot of the ligation 
product and then separated electrophoretically. Once the presence of the amplicon was confirmed in 
agarose gel, the ligation product was transformed into BL21 and KRX competent cells for protein 
expression. The conditions for transformation are similar to the ones described in 3.3.4.3.1 above. 
Upon confirmation of recombinant plasmid by colony PCR, a small-scale protein expression was 
performed in KRX cells.  
 
3.3.5. Expression of full length GST-tagged human cyclophilin A in E.coli cells   
3.3.5.1. Optimization of protein expression conditions 
Starter cultures supplemented with 0.4 % Glucose (1:50 dilution of 20 % glucose) were grown 
overnight in LB medium containing ampicillin at 37 
o
C with shaking at approximately 275 rpm. 
These were diluted 1:100 with LB containing ampicillin, and thereafter they were grown at 37 
o
C 
with shaking until they reached an OD600 of 0.8-1.0. This was followed by addition of Rhamnose 
and IPTG to a concentration of 0.1 % (1:200 dilution of 20 % Rhamnose) to induce protein 
expression and then incubated overnight at 37 
o
C with shaking.  
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3.3.5.2. Protein analysis 
3.3.5.2.1. Preparation of cell lysates  
Following the overnight expression reaction, the recovery of cells from LB medium post-expression 
was done by means of centrifugation, followed by quick freezing and then stored overnight at -80 
o
C. Frozen cells were thawed, resuspended with 0.5 % TritonX100 and Protease inhibitor, and then 
lysed by sonication. Cytoplasmic proteins were separated from cell debris (membrane-bound 
proteins) by means of centrifugation at 6 000 rpm for 30 min. The latter was re-suspended in 30% 
glycerol at room temperature (20-25 
o
C) followed by vigorous vortexing and pippeting. This cell 
suspension was incubated for 20-30 min at room temperature with shaking followed by thorough 
re-suspension to obtain a uniform suspension.  Both cytoplasmic and membrane proteins were 
diluted with protein loading buffer in a ratio of 1:1 followed by analysis on sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and then detected by means of Western Blot.  
 
3.3.5.2.2. SDS-PAGE of total proteins 
For SDS-PAGE analysis, sterile gel plates were assembled and verified for any leakages. 15 % of 
sodium dodecyl sulfate (SDS) gel was prepared using these plates according to the Fluka (Sigma) 
specifications. The 15 % separating gel (Acrylamide/Bisacrylamide-stock solution [30:0.8 %], 
separating gel buffer [pH 8.8]) and stacking gel (Acrylamide/Bisacrylamide-stock solution [30:0.8 
%], stacking gel buffer [pH 6.8]) were each polymerized by addition of 0.8 % (w/v) ammonium 
persulphate (APS) and 10 % of tetramethylene diamine (TEMED) solution. For quality purpose, 
APS (10 % w/v) was prepared every week. Prior to sample loading into gel wells, a 1.5:1 mix ratio 
of protein sample with SDS loading dye was performed. Approximately 25 µl and 10 µl of total 
protein and protein marker, respectively, were loaded into protein wells. These were separated 
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using a Hoefer electrophoresis unit in SDS running buffer (25 mM Tris, 192 mM Glycine, 0.1 % 
(w/v) SDS (pH 8.3)) and proteins were separated according to their electrophoretic ability applying 
constant current at 20 amperes per gel. Following electrophoresis, the gel was stained overnight 
with Coomassie brilliant blue ([40 % (v/v) methanol, 10 % (v/v) acetic acid and 0.025 % (w/v) 
Coomassie brilliant blue R250]) and then de-stained in a solution containing 30 % methanol, 10 % 
glacial acetic acid and 60 % distilled H20, until the protein bands were visible. Alternatively the 
proteins were subjected to Western Blotting for detection of fusion proteins using specific 
antibodies. 
 
3.3.5.2.3. Western blot analysis of total proteins 
Prior to transfer the nitrocellulose membrane was equilibrated in 20 % (v/v) methanol. Proteins 
were transferred in transfer buffer (27 mM tris(hydroxymethyl)-amino-methane, 191 mM 
glycine and 20 % (v/v) methanol) in a submersion system at 100 V for 90 min. Next, the 
membrane was blocked with 3 % (w/v) milk in 0.05 % (v/v) Tween-20 in PBS solution for 30 
min on a rocker at room temperature. The membrane was then incubated in primary antibody 
rabbit anti-GST in 3 % (w/v) milk in 0.05 % (v/v) Tween-20 in PBS solution (1:5000) overnight 
at 4 
o
C with rolling. This was followed by washing any unbound antibodies with PBS/0.05 % 
Tween for 45 min at 15 min intervals and then covered with HRP-conjugated goat anti-Rabbit 
(secondary antibody) for 60 min in 3 % (w/v) milk in 0.05 % (v/v) Tween-20 in PBS solution at 
a 1:2 000 ratio. The membrane was again washed twice with PBS/0.05 % Tween at 30 min 
intervals to again remove any unbound secondary antibody and thereafter 1 000 µl of 1 
Component TMB membrane peroxidase substrate was added on the membrane to detect the 
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presence of recombinant protein from the total bacterial proteins. The presence of the protein of 
interest was indicated by the appearance of a purple color on the nitrocellulose membrane. Once 
the protein band became distinctly visible, the membrane was rinsed with PBS/0.05 % Tween 
and air dried.  
 
3.3.5.2.4. Quantification of total protein concentration  
For quantification of proteins, a Qubit-iT
TM
 Assay was used. 199 X n µl of Quant-iT
TM
 buffer 
(where n represents the number of standards plus number of samples) was mixed up with 1 x n µl of 
Quant-iT
TM
 reagent to a make up a Quant-iT
TM
 working solution. 190 µl of the latter was then 
mixed with 10 µl of standards, whereas 180-199 µl of working solution was mixed with user 
samples to make up a final volume of 200 µl. Following equilibration of the Qubit
TM
 fluorometer 
with known standards, fluorometer readings were taken and the concentrations (mg/ml) were 
calculated using the formula C = QF x 200/10 (where QF = Qubit fluorometer reading, C = 
concentration). Protein concentration was also estimated by means of Coomassie stain. Known 
BSA standards of varying concentration were run with total protein on SDS-PAGE and then stained 
with Coomassie. The concentration of total protein was estimated based on the degree-of-similarity 
of band intensity between the known BSA standards and total protein.    
 
3.3.6. Purification of recombinant protein  
3.3.6.1. Small scale purification  
After induced bacterial expression, 100 ml of bacterial culture was pelleted by means of 
centrifugation at 14 000 rpm for 30 min. The pellet was resuspended with 2 ml of 1 %Triton and 40 
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µl of Protease inhibitor per gram of cell pellet. The pre cooled cell suspension was lysed using 
sonication followed by centrifugation at 14 000 rpm for 30 min. The cleared lysates was subjected 
to purification according to Promega standards using MagneGST
TM
 protein purification system. 100 
µl of the thoroughly re-suspended MagneGST particles was pippeted into a 1.5 ml eppindorf tube. 
The particles were captured by placing the tube on a magnetic stand and the resulting supernatant 
was discarded. The particles were re-suspended and washed by 250 µl of Binding/Washing buffer 
for a total of three washes. After the final wash, the particles were re-suspended with 100 µl of 
Binding/Washing solution. To bind the cell lysate to the MagneGST particle, 500 µl of the cell 
lysate was added to the particles and then incubated at room temperature for 30 min with shaking. 
After incubation, the supernatant was aspirated meanwhile the particles were washed with 250 µl of 
Binding/Washing buffer for a total of three washes. After the final wash, 100 µl of elution buffer 
was added followed by incubation at room temperature for 15 min with gentle shaking. The 
particles were then captured by placing the tube on a magnetic stand while the purified GST-fusion 
was being aspirated from the supernatant and stored at -20 
o
C for further analysis.  
 
3.3.6.2. Large-scale protein purification  
After the small-scale purification was performed with successful purification of the protein of 
interest, a large scale was carried out in order to obtain a higher yield of the protein of interest. For 
large-scale protein purification the Pierce
® 
GST spin purification kit was used. 500 ml of cell 
culture was pelleted by centrifugation at 14 000 rpm for 30 min and the supernatant discarded. The 
bacterial pellet was suspended in 4 ml 1 %Triton and 40 µl of Protease inhibitor by vortexing 
and/or vigorous pippeting until a homogeneous cell suspension was attained.  This was followed by 
a centrifugation step at 14 000 rpm for 30 min to separate soluble proteins from insoluble proteins. 
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The protein of interest in the supernatant was then purified according to specification of Pierce
® 
GST spin purification kit.  
 
3.4. RESULTS 
3.4.1. Generation of recombinant plasmid 
The primers specific for the gene of interest were successfully designed and prepared to the 
desired concentration of 100 ρ.mole/μl stock solutions. Secondly, mRNA was extracted from 
MCF7 cells and reverse transcribed into cDNA. The latter was amplified by means of PCR into 
multiple copies of CypA. In figure 3.1, the sizes of the amplified human gene, CypA, is clearly 
shown. The lane represented by “M” indicates the 100 bp DNA marker with molecular weights 
specified along the left margin of the figure. On the same figure the house-keeping gene PBDG 
served as a positive control. This 396 bp gene is represented in lane 1 and 2 and appears as a 
faint band. The presence of PBDG on this figure confirms the presence of cDNA in the reaction 
thereby eliminating any false positive results. Furthermore, the results clearly indicate that the 
gene of interest was amplified from the cDNA library using these gene specific primers. This 
498 bp DNA fragment is clearly indicated in lane 3. 
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Figure 3.1: Agarose gel electrophoretic analysis of human cyclophilin A that has been 
amplified by Polymerase Chain Reaction using gene specific primers. “M” represents 
the 100 bp DNA ladder. The sizes of the DNA molecular weight are indicated on the left 
of the figure in base pairs. Lane 1 and 2 represent the housekeeping gene, 
Porphobilinogene Deaminase (PBDG) (396 bp), which serves as a positive control. Lane 
3 represents the gene of interest, CypA (498 bp).  
 
Following amplification of the CypA gene, the amplicon was successfully cloned into pGEM vector 
and later confirmed by means of blue/white selection following transformation into JM109 
competent cells. The presence of white colonies on agar plates represented cells that were 
transformed, whereas blue/dark colonies represented untransformed cells. Moreover, successfully 
transformed cells were verified by means of colony PCR as indicated in figure 3.4. Following 
plasmid isolation from the transformed cells, the presence of the exact protein coding region of 
CypA was initially verified by restriction digest of pGEM with EcoR1 and the presence of the DNA 
fragment is shown in figure 3.2, whereas the correct DNA sequence after sequencing is shown in 
figure 3.3. In figure 3.2, the 3 kbp DNA band on top of each lane represents the cleaved vector, 
whereas the bottom bands represent the genes of interest. Lane “M” represents the 100 bp DNA 
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ladder with molecular weights indicated on the left margin of the figure. Lane 1 and 2, on the other 
hand, represent cleaved pGEM vector, (3 kbp) that was cloned with hnRNP A1 (900 bp) and Lane 3 
and 4 represent cleaved pGEM (3 kbp) that was cloned with CypA (498 bp). 
 
 
Figure 3.2: pGEM vector cleaved with restriction endonuclease EcoR1. The 3 kbp DNA 
on top of each lane represents the vector, whereas the bottom band represents the gene of 
interest. Lane “M” represents the 100 bp DNA ladder with molecular weights indicated on 
the left margin of the figure. Lane 1 and 2 represent cleaved pGEM vector (3 kbp) that was 
cloned with hnRNP A1 (900 bp), whereas lane 3 and 4 represent cleaved pGEM (3 kbp) 
that was cloned with CypA (498 bp). 
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In figure 3.3 below, the dark/black regions in this diagram represent homologous nucleotide 
sequences between the amplified gene of interest and known NCBI sequences. From this figure it is 
clearly evident that there is 100 % homology between the two compared sequences, meaning that 
there were no mutations or mismatching of bases on the gene of interest.  
 
Figure 3.3: Sequence verification by comparing cyclophilin A (CypA) cloned into pGEM 
vector with known CypA sequence extracted from NCBI. Homologous regions between 
NCBI sequences and the cloned insert are represented by dark regions that stretch from 
25-523 nucleotides. From the figure, it is clear that there is 100% homology between the 
cloned and known CypA sequence.  
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After the correct protein coding region was confirmed in pGEM vector it was later shuttled to a 
bacterial expression vector, pFlexi, which has been cut with the Pme1 and Sgf1 restriction enzymes. 
Successful shuttling of the protein coding into a bacterial expression vector (pFlexi) was verified by 
means of colony selection and colony PCR subsequent to transformation into KRX competent cells. 
Figure 3.4 indicates successful transformation of CypA genes onto KRX cells. From figure 3.4 it is 
clear that pFlexi was successfully cloned and transformed into competent cells.  
 
 
Figure 3.4: Colony PCR confirming the presence of CypA gene that has been transformed 
into KRX competent cells. On the figure “M” represent the 100 bp DNA ladder with 
molecular weights indicated along the left margin of the figure. Lane 1-8 represents 
successful transformation of CypA (498 bp) and lane 9 indicates the positive control.  
 
 The presence of the amplicon in pFlexi was again confirmed by means of restriction endonuclease 
digest and this phenomenon is shown in figure 3.5. This figure shows the presence of the gene and 
the vector following digestion with restriction enzymes. The approximately 4 kbp vector is 
presented on top of the figure in each lane of the agarose gel. On the other hand, the gene of interest 
presents at the bottom of lane 2 as a single band. Lane “M” on the figure represents the 100 bp 
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DNA ladder. Lane 1 represents the uncut plasmid that has been cloned with CypA. Lastly, lane 2 
represents pFlexi/CypA that has been digested with Pme1 and Sgf1.  
 
 
Figure 3.5: pFlexi cleaved with restriction endonucleases, Sgf1 and Pme1. Lane “M” 
represents the 100 bp DNA marker with molecular weights indicated along the left margin 
of the figure. Lane 1 and 2 represent uncut and cut pFlexi vector, respectively.  The top 
bands in lane 1 and 2 with ~4 kbp indicate the cut pFlexi vector, whereas the 498 bp DNA 
band in lane 2 is CypA.  
 
3.4.2. Expression and protein analysis in E.coli cells 
Total proteins were successfully expressed and analyzed using SDS-PAGE, Coomassie blue and 
Western blot. Figure 3.6 represents total proteins, both cytoplasmic and membrane, expressed 
within the bacterial cells. From the figure it is evident that there is a multitude of proteins with 
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different molecular weight. The 42 kDa protein, CypA, is not apparent from total proteins as there 
are other proteins that are highly expressed in comparison to the protein of interest.                   
 
Figure 3.6: Coomassie stain showing the lysate of all expressed proteins.  Lane “M” represents 
the protein marker with molecular weight designated along the left margin of the figure. Lane 1 
represents cyctoplasmic proteins of E. coli, whereas lane 2 represents membrane proteins of E. 
coli.  
 
Despite the indistinct appearance of CypA gene on Coomassie blue, we have managed to detect its 
presence from the total proteins by means of Western blotting. The dark band in figure 3.7 below 
indicates the GST-tagged protein that has been detected in nitrocellulose membrane using specific 
antibodies. From the results it is evident that the technique is highly specific to the GST tag that 
was fused to the protein of interest.  
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Figure 3.7: Western blot analysis depicting the expression of CypA in E. coli. Lane 
“M” represents the pre-stained protein marker with molecular weights designated along 
the right hand margin of the figure. The 42 kDa CypA is illustrated in lane 1 and 2 as a 
distinct purple band.  
 
3.4.3. Purification of recombinant protein 
The purification of recombinant protein was done using MagneGST protein purification system. 
Following optimization of protein expression the presence of CypA protein was confirmed by 
small-scale purification. The fusion proteins were successfully purified in small scale and this is 
clearly obvious in figure 3.8 below. After comparing the protein concentration of CypA with known 
BSA standards, it is appreciable that the purification step yielded low concentrations of the protein 
of interest. In figure 3.8, lanes 2-6 represent the known BSA standards in increasing concentration: 
0.125 mg/ml, 0.25 mg/ml, 0.5 mg/ml, 0.75 mg/ml, 1.5 mg/ml, and 2 mg/ml. The measured 
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concentration of CypA using Qubit fluorometer revealed a concentration of 0.246 mg/ml and this 
corresponds to the 0.25 mg/ml BSA standard that is represented in lane 3.  
 
 
Figure 3.8: Coomassie stain showing small-scale purification of CypA protein. Lane “M” 
represents the pre-stained protein molecular marker. Lane 1 indicates purified CypA with 
a concentration of 0.246 mg/ml. Lane 2-6 represent bovine serum albumin (BSA) 
standards in increasing concentration: 0.125 mg/ml, 0.25 mg/ml, 0.5 mg/ml, 0.75 mg/ml, 
1.5 mg/ml, and 2 mg/ml. The intensity of the Cyp A band in lane 1 corresponds more or 
less with that of lane 3, which is measuring 0.25 mg/ml. 
 
3.5. DISCUSSION AND CONCLUSION 
CypA is a peptidyl-prolyl cis/trans isomerase (PPIA) that is involved in several signaling events of 
eukaryotic cells. CypA plays key roles in several different aspects of cellular physiology including 
the immune response, transcription, mitochondrial function, cell death, and chemotaxis. Because of 
their multiple functions elucidation of their mechanism of action received major attention and 
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therefore, became an active area of research. In comparison to CypB and CypC, which do not seem 
to exhibit much affinity for viruses, CypA has been shown to interact with capsid proteins of viral 
origin. In addition, CypA was previously reported to be associated with several tumor types but 
following its association with HIV-1 capsid protein it became evident that these traits can be 
exhibited in other viral capsid proteins. The CypA interaction with viral proteins was originally 
described for HIV-1 capsid protein (Zander, Sherman et al. 2003). Following extensive research on 
CypA it was later discovered that CypA interacts with other viral capsid proteins and more recently 
with hepatitis C virus capsid and SARS nucleocapsid protein. Most notably, in some studies these 
interactions have been mapped around a specific amino acid residue that seems to exhibit 
considerable affinity for capsid proteins. Most of these studies have revealed that these interactions 
are centered on the proline residue even though the proline position is not necessarily the same 
(Zander, Sherman et al. 2003). Therefore, it is suffice to say that proline is the stereochemically 
active site for interaction with capsid proteins. 
 The present study was specifically designed to investigate the interaction of HCoV NL63 
nucleocapsid protein and its truncated mutants with human cyclophilin A protein. This study 
follows the discovery of the SARS-N protein that was reported to exhibit direct and specific 
binding affinity to CypA. Given the evolutionary relationship between SARS CoV and HCoV 
NL63, it is reasonable to infer that the same kind of interaction that is observed with SARS-N 
protein will also be demonstrated by NL63-N protein. Furthermore, the study seeked to identify the 
exact domain of nucleocapsid protein that exhibits direct and specific interaction with human 
CypA. The outcomes of these interaction studies will shed light to some of the therapeutic strategies 
that could be explored to prevent the virus from causing disease.  
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 Initially, the protein of interest was characterized by means of in silico analysis. Using an 
array of molecular techniques, CypA was then characterized both qualitatively and quantitatively. 
The protein of interest was successfully extracted from MCF7 cells, amplified by means of RT-
PCR and then cloned into a bacterial expression vector. The latter was verified by automated 
genome sequencing, transformed into KRX cells and then expressed in a bacterial system. 
However, the key challenge for achieving the desirable protein yield was with the expression vector 
and competent cells. As a result, CypA was expressed in two different tags viz. GST- and HQ. 
However, it was noticeable that the patterns of expression differ between the two tags. Most 
notably, the expression vector requires IPTG to bind to the T7 promoter to induce protein 
expression. Competent cells, on the other hand, seem to be inhibited by addition of the inducer. 
Therefore, it is reasonable to assume that IPTG has toxic properties towards the competent cells; 
hence the observed protein yield. Secondly, because of the abovementioned properties of the 
expression vector the optimum OD600 requirements to induce protein expression had to be varying 
in order to obtain optimum expression. Additionally, the time frames to incubate cultures following 
protein expression had to fluctuate before attaining the desirable protein yield. The explanation for 
this variation in expression patterns remains obscure. Lastly, it is noticeable from the results that 
there is a sharp decline in protein concentration levels between cell lysates and purified protein. 
This can be attributed to proteolytic cleavage of expressed protein by cell proteases merely because 
CypA is a human protein, therefore, in a bacterial system it is recognized as foreign.  
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4.1. ABSTRACT 
Cyclophilins (Cyp) are a family of proteins that possess peptidyl-prolyl cis-trans isomerase activity 
and play a key role in the folding of proteins (Lee 2010). They have been reported to be associated 
with several diseases and most commonly with severe types of carcinoma but their role remain 
unclear. CypA is the first member of mammalian cyclophilins to be identified and it plays key roles 
in several different aspects of cellular physiology including the immune response, transcription, 
mitochondrial function, cell death, and chemotaxis (Galat and Bua 2010). In addition to these key 
physiological functions of CypA, it has also been reported to interact with viral proteins, especially 
caspid proteins. Most recently, it has been revealed to interact with severe acute respiratory 
syndrome (SARS) nucleocapsid (N) protein. SARS emerged in 2002-2003 as a coronavirus from 
Southern China and spread throughout the world (Wang, Ji et al. 2003; Lu, Zhao et al. 2004; Hao, 
Chen et al. 2006). Coronaviruses are enveloped single stranded positive sense RNA viruses about 
80-160 nm in diameter. SARS generally cause disease much like the common cold, but they have 
also been associated with more severe lower respiratory tract conditions, especially in frail patients 
(Woo, Lau et al. 2005; Dijkman, Jebbink et al. 2006; Shao, Guo et al. 2007). For the purpose of this 
study, the focus is based on CypA interaction with HCoV NL63-N protein. These interactions 
might play a role in the pathology of HCoV-NL63. Using Glutathione-S-transferase (GST), the 
interaction of CypA with nucleocapsid protein can be demonstrated to be direct and specific. Since 
the N protein is involved in viral RNA packaging to form a helical core, it is suffice to say that both 
NL63-N and CypA are possibly within the HCoV-NL63 replication/transcription complex and 
NL63-N/human CypA interaction might function in the regulation of HCoV-NL63 RNA synthesis.   
In addition, the study intends to demonstrate that HCoV-NL63-N has a specific domain for 
interacting with CypA. 
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4.2. INTRODUCTION 
Coronaviruses and toroviruses are members of the Coronaviridae family, which along with the 
Roniviridae and Arteriviridae families form the order Nidovirales. Coronaviruses are responsible 
for approximately 30% of human upper respiratory infections each year (Yeung, Yamanaka et al. 
2006). In November 2002, SARS emerged in China and caused more than 8 000 cases of SARS 
worldwide (Zhou, Liu et al. 2008). Approximately 10% of these cases were fatal.  Coronaviruses 
are categorized into three groups based on their serologic and genotypic characteristics. Group 1 
and 2 contain mammalian viruses, while group 3 consists of avian viruses. Group 2 viruses are also 
characterized by the presence of a gene encoding the heamaglutinin esterase (HE) protein, which is 
absent in the other groups (Dijkman, Jebbink et al. 2006; Frieman, Yount et al. 2007; Dijkman, 
Jebbink et al. 2008).  
All coronaviruses are enveloped single stranded positive sense RNA viruses about 80-160 
nm in diameter. Their genome has the following gene order: 1a-1b-S-ORF3-E-M-N. The 5′-two 
thirds of the genome encodes for a polyprotein that contains all the enzymes necessary for 
replication, whereas the 3′-one third encodes for all the structural proteins that mediate viral entry 
into the host cell (Hogue and Brian 1986; Hao, Chen et al. 2006; Junwei, Baoxian et al. 2006). The 
structural proteins include spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. 
Nucleocapsid (N) protein has been shown to be the major antigen in coronaviruses (Lu, Pan 
et al. 2011). It is encoded by the ninth open reading frame (ORF) of SARS, which is the same ORF 
that encodes for an accessory protein called ORF9, but they have different ORFs (Hogue and Brian 
1986; Almazan, Galan et al. 2004; He, Leeson et al. 2004; Shang, Qi et al. 2006; Muller, van der 
Hoek et al. 2010). This particular protein has the capability to regulate cellular signal pathways 
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such as arresting cell cycle progression, inducing apoptosis and actin reorganization and activating 
the AP-1 signal transduction pathway (Kang, Plescia et al. 2007; Emmott, Rodgers et al. 2010; Li, 
Lai et al. 2011). Furthermore, N protein plays an imperative role in viral core formation and viral 
packaging. It has also been shown to interact with cellular proteins including CypA, hnRNP A1, 
human ubiquitin-conjugating enzyme and CDK-cyclin complex proteins, IkBα, Cyt P450 2A6 etc. 
Even more interesting, this protein is known to interact with other structural proteins i.e. membrane 
protein, and also has the capability to self-associate (Klumperman, Locker et al. 1994; Chan, Ma et 
al. 2007; Bai, Hu et al. 2008; Liu, Sun et al. 2010).  
The literature indicates that interaction between SARS-N and M protein in vivo takes place 
along a specific stretch of amino acids found in the N protein. The same region has been discovered 
to be the region required for multimerization of the N protein suggesting that it may be crucial in 
maintaining correct conformation of the N protein for self-interaction and interaction with the M 
protein (Schaecher, Diamond et al. 2008; Liu, Sun et al. 2010). The M-N interactions are known to 
be crucial for viral assembly and morphogenesis. Luo et al (2004) have mapped M and N protein 
interacting regions using yeast two hybrid and surface plasmon resonance technique, to residues 
197-221 and 351-422, respectively (He, Leeson et al. 2004; Chan, Ma et al. 2007). These fragments 
were shown to be highly charged at neutral pH, suggesting that their interaction may be of ionic 
nature. However, this interaction was shown to be weakened by acidification, higher salt 
concentration (400 mM NaCl) and divalent cations (50 mM Ca
2+
), which suggests that electrostatic 
attraction might play a role in this interaction (Liu, Sun et al. 2010). The latter could provide a 
possible therapeutic strategy aiming at disrupting association between M and N protein. However, 
in mouse hepatitis virus (MHV) and transmissible gastroenteritis virus (TGEV) the stretch of amino 
acids where these interactions occur were mapped at different locations. Residues 201-224 of 
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MHV-M protein and residues 233-257 of TGEV-M protein were mapped to be involved in the M-N 
protein-protein interaction (Wesseling, Godeke et al. 1993; Versteeg, van de Nes et al. 2007; Ye, 
Hauns et al. 2007). 
The property of self-association of the N protein is of crucial importance, because some 
laboratories have some interesting discoveries. Dimer formation has been observed both for 
recombinant proteins as well as during viral infection. Some researchers have shown that the 
recombinant full length N protein is dimeric with the propensity to form tetramers and higher 
molecular weight oligomers. However, the homodimer formation of the N-homodimer has been 
shown to be inhibited by excess truncated mutant containing the dimerization domain (He, Leeson 
et al. 2004; Tang, Wu et al. 2005). These oligomerization domains of N protein were mapped 
through studies of the oligomeric states of several truncated mutants. SARS-N carboxy (C)-terminal 
domain has proven to be the site of dimerization at 285-422 amino acid residues (Schreiber, 
Kamahora et al. 1989). Therefore, the dimerization domain is mapped to the C-terminal 138 
residues, and the homodimer formation is inhibited by excess truncated mutants containing the 
dimerization domain. The two domains of the N protein viz. amino (N) - and C-terminal domains 
are believed to play the above mentioned roles. The N-terminal domain, which is known to bind 
RNA exhibits relatively long sequences of positively, charged amino acids. C-terminal, on the other 
hand, possesses a lysine rich region (373-390), which is predicted to be nuclear localization signal 
(NLS) (Timani, Liao et al. 2005; Emmott, Dove et al. 2008). Previous studies have determined the 
dimerization domain at the C-terminal but at different amino acid residues. Another study 
determined that the serine/arginine (SR)-rich motif is crucial for N-N oligomer formation and 
deletion of this motif lead to loss of N-N interaction (He, Leeson et al. 2004; Calvo, Escors et al. 
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2005; You, Dove et al. 2005). Researchers believe that this self-association may play a role in 
ribonucleoprotein formation and subsequently in the viral assembly process.   
As previously mentioned, the M protein interacts with the mid-portion of the N-protein. 
Surprisingly, the same region also interacts with hnRNP A1, and structural studies have identified 
the region between amino acid 45-181 as the putative RNA binding region, which is close to the N-
terminus (Luo, Chen et al. 2005). The MHV-N protein was first shown in 1986 to have RNA 
binding activity by North western assays (Klumperman, Locker et al. 1994; Schickli, Zelus et al. 
1997; Luo, Chen et al. 2005). Although there is no sequence homology to previously described 
RNA-binding motifs, the central domain of N protein has been shown to be the RNA binding 
region. The N protein is known to interact with viral RNA genome to form a helical nucleocapsid 
structure. This interaction plays a role in a number of viral processes including viral RNA 
dependent RNA transcription, genome replication and translation. Nucleic acid binding activity of 
N-protein has been extensively studied for MHV, bovine coronavirus (BCV) and infectious 
bronchitis virus (IBV), and this particular interaction was found to be specific to viral RNA and not 
affected by addition of non-specific competitor RNA. The amino acid residues where N protein 
interacts with RNA exhibit differences in location, but they have been found to be rich in serine and 
arginine residues. This motif is known to be conserved in all coronavirus N protein (Cavanagh 
2003; Zuniga, Sola et al. 2004; You, Reed et al. 2007).  
The main purpose of this study is the interaction of NL63-N protein with CypA. The 
coronavirus N proteins exhibit high binding affinity to CypA and this association has been 
established in SARS-N protein studies. In addition to CypA, the nucleocapsid protein is known to 
exhibit similar binding affinity to hnRNP A1 and this binding was initially established with MHV-
N protein. The binding site of hnRNP A1 with MHV-N protein was determined in two regions of 
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the protein using yeast two hybrid assay (Luo, Chen et al. 2005). These included N-terminal region 
(1-292) and C-terminal end (391-455). Recently this association was mapped to the 161-210 amino 
acid fragment of SARS-N protein and to the 203-320 glycine rich region of hnRNP A1. If this 
interaction is in vivo, it may play a significant role in regulation of the viral RNA synthesis. 
Moreover, hnRNP A1 has been demonstrated to interact direct and specific, in vitro and in vivo, 
with IkBα and this interaction is required for maximum activation of nuclear factor kappa light-
chain enhance of activated B cells (NF-kB)-dependent transcription. Thus, in addition to regulating 
splicing, polyadenylation, and mRNA transport, hnRNP A1 also contributes to the fine control of 
NF-kB-dependent transcription (Luo, Chen et al. 2005). The region in hnRNP A1 which is required 
for interaction with IkBα is located between residues 95-207. Literature indicates that in cells 
lacking hnRNP A1, NF-kB activation is defective but re-introduction of hnRNP A1 into these cells 
restores an efficient NF-kB response to signal transduction (Fang, Gao et al. 2007). NF-kB is a 
protein complex that acts as a transcription factor, and it plays a key role in regulating immune 
response to infection. Incorrect regulation of this complex has been linked to cancer, inflammatory 
and auto-immune diseases, septic shock, viral infection and improper immune development. 
Therefore, if HCoV-N protein interacts with hnRNP A1, the activation of NF-kB will be defective 
resulting in the above mentioned consequences. This interaction is mediated by the C-terminal 
region of IkBα and one of the N-terminal RNA binding domains of hnRNP A1.  
In addition to self-association, interaction with viral RNA, hnRNP A1, CypA and M 
protein, some studies have discovered that SARS-N also interacts with human phosphoprotein B23 
both in vitro and in vivo, and this interaction is dependent on SR-rich domain (175-210) in the N 
protein (Yuan, Yao et al. 2005; Zeng, Ye et al. 2008). The ultimate result of this interaction is 
inhibition of phosphorylation of B23 at Thr99. Since B23 plays a role in centrosome duplication 
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during cell cycle progression, the SARS-N-B23 interaction can lead to cell cycle arrest since the 
centrosome cannot initiate duplication (Zeng, Ye et al. 2008).   
These protein interactions form the basis of this study. Determination of these interactions 
and identification of amino acid sequences responsible for these interactions are necessary for the 
elucidation of molecular mechanisms of HCoV-NL63 replication and rationalization of therapeutic 
intervention. This can be achieved by means of protein tagging, because this technique facilitates 
protein detection using a peptide. This allows detection and affinity purification of a protein in the 
absence of a specific antibody against the protein of interest. Previous studies have shown that these 
interactions amongst various coronaviruses are critical for viral assembly as well as infection 
process.   
 
4.3. MATERIALS AND METHODS 
4.3.1. Plasmid DNA isolation 
The glycerol stocks of GST tagged nucleocapsid genes cloned into pFlexi vector were kindly 
provided by Mr. Berry (University of the Western Cape, Department of Medical Biosciences). The 
genes included SARS-N and NL63-N gene. In addition to the full length gene of NL63, the gene 
was also designed in such a way that it was truncated into C-terminal and N-terminal domains. In 
this study, these genes are designated as SARS-N, N1, N2 and N3 for the full length SARS-N, full 
length NL63-N, C-terminal NL63-N, and N-terminal NL63-N gene, respectively. Table 4.1 
provides a brief description of these genes as well as GST that was used to tag the proteins.  
 
 
 
 
 
 
Chapter 4 
 
80 
 
Table 4.1: Plasmid constructs used in this study. 
Construct Name Description of recombinant GST-tagged protein 
N/A
# 
GST tagged protein control to confirm plates were adequately coated 
GST GST only to confirm antigenicity detected was not directed against  
the fusion protein 
SARS-N SARS-CoV full length N (a.a. 1-423) 
N1 HCoV-NL63 full length N (a.a. 1-378) 
N2 N-terminal half of the HCoV-NL63 N (a.a. 1-189) 
N3 C-terminal half of the HCoV-NL63 N (a.a. 191-378) 
#
N/A – Not applicable 
 
4.3.2. Restriction endonuclease digestion 
The glycerol stocks were spread on Luria Bertani (LB)-agar plates Luria Bertani (LB) broth (10 g 
pancreatic digest of casein, 5 g yeast extract powder, 5 g  NaCl, and 15 g of agar bacteriological per 
1L water) supplemented with ampicillin (100 mg/ml) and incubated overnight (12-16 hours) at 
37
0
C. Colonies were selected for PCR as well as inoculation onto 15 ml of LB broth. Once the 
presence of the correct genes was verified in gel electrophoresis, the cultures that correspond to the 
confirmed colonies were used for plasmid DNA isolation using the Wizard plus SV Minipreps 
DNA purification system. Furthermore, glycerol stocks were prepared from these cultures. The 
presence of the exact gene was further confirmed by restriction enzyme digest following the 
plasmid isolation from the competent cells. Table 4.2 illustrates the standard reaction that was 
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performed when conducting restriction digests. Aliquots of these constructs were digested with 
pFlexi restriction enzymes (Sgf1 and Pme1). 
 
Table 4.2: pFlexi restriction enzyme digests. 
Reagent  pFlexi enzyme digest reaction (µl) 
5 x Flexi digest buffer  2 
DNA constructs  10 
Sgf 1and PmeI enzyme blend 2 
Nuclease free water 4 
 
4.3.3. Expression of the nucleocapsid proteins in E. coli cells 
4.3.3.1. Optimization of expression conditions 
The conditions for protein expression were optimized using the prepared glycerol stocks. Starter 
cultures supplemented with 0.4 % Glucose (1:50 dilution of 20 % glucose) were grown overnight in 
LB medium containing ampicillin (100 mg/ml) at 37 
o
C with shaking at approximately 275 rpm. 
These were diluted 1:100 with LB containing ampicillin, and thereafter they were grown at 37 
o
C 
with shaking until they reached an Optical Density (OD600) of 0.8-1.0. This was followed by 
addition of Rhamnose (10 %) and IPTG (100 mM) to a concentration of 0.1 % (1:200 dilution of 20 
% Rhamnose) to induce protein expression and then incubated overnight at 37 
o
C with shaking.  
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4.3.3.2. Protein analysis 
4.3.3.2.1. Preparation of cell lysate  
Following the overnight expression reaction, the recovery of cells from LB medium post-expression 
was done by means of centrifugation, followed by quick freezing and then stored overnight at -80 
o
C. Frozen cells were thawed, resuspended with 0.5 % TritonX100 and Protease inhibitor (1 ml per 
4 g of cells), and then lysed by sonication. The cytoplasmic proteins were separated from cell debris 
(membrane proteins) by means of centrifugation at 6 000 rpm for 30 min. The later was re-
suspended by 30 % glycerol at room temperature (20-25 
o
C) followed by vigorous vortexing and 
pippeting. This cell suspension was incubated for 20-30 min at room temperature with shaking 
followed by thorough re-suspension to obtain uniform suspension.  Both cytoplasmic and 
membrane proteins were diluted with protein loading buffer in a ratio of 1:1 followed by analysis 
on SDS-PAGE and then detected by means of Western Blot.  
 
4.3.3.2.2. SDS-PAGE analysis 
For SDS-PAGE analysis, sterile gel plates were assembled and verified for any leakages. 15 % of 
SDS gel was prepared using these plates according to the Fluka specifications. For quality purpose, 
APS (10 %w/v) was prepared every week. Prior to sample loading into gel wells, a 1.5:1 mix ratio 
of protein sample with loading dye was performed. Approximately 25 µl and 10 µl of total protein 
and protein marker, respectively, were loaded into protein wells. These were separated according to 
their electrophoretic ability applying constant current at 20 amperes per gel. Following this reaction 
the gel was either submerged in Commassie stain (45 % methanol, 10 % glacial acetic acid, 45 % 
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water, and 3 g/L Coomasie brilliant blue R250) overnight or subjected to Western blotting for 
further experiments.  
 
4.3.3.2.3. Western blotting of total proteins 
The separated proteins were transferred to a nitrocelullose membrane for Western blot studies. The 
SDS gel was transferred to a Western blot transfer system covered with nitrocellose membrane that 
has been sandwiched with Whatmann paper and sponges immersed in pre-cooled transfer buffer. 
The experiment was carried out at 4 
o
C with the transfer system running at 100 V and constant 
amperes for a period of 120 min.  
On completion of the transfer, the nitrocellulose membrane was immersed in Ponceau stain 
with shaking for 3 min and then blocked with 3 % (w/v) milk for approximately 30 min. The 
membrane was then exposed to Rabbit anti-GST (primary antibody) in a ratio of 1:5000 overnight 
at 4 
o
C. This was followed by a washing step with PBS/0.05 % Tween for 45 min at 15 min 
intervals and then covered with Goat anti-Rabbit (secondary antibody) for 60 min in a 1:2 000 ratio. 
The membrane was again washed twice with PBS/0.05 % Tween at 30 min intervals and thereafter 
1 000 µl of 1 Component TMB membrane peroxidase substrate was added on the membrane to 
detect the presence of recombinant protein from the total bacterial proteins. The presence of the 
protein of interest was indicated by the appearance of a purple color on the nitrocellulose 
membrane.  
 
4.3.3.2.4. Quantification of protein concentration 
For quantification of proteins, a Qubit-iT
TM
 Assay was used. 199 x n µl of Quant-iT
TM
 buffer 
(where n represents the number of standards plus number of samples) was mixed up with 1 x n µl of 
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Quant-iT
TM
 reagent to a make up a Quant-iT
TM
 working solution. 190 µl of the latter was then 
mixed with 10 µl of standards, whereas 180-199 µl of working solution was mixed with user 
samples to make up a final volume of 200 µl. Following equilibration of the Qubit
TM
 fluorometer 
with known standards, fluorometer readings were taken and the concentrations (mg/ml) were 
calculated using the formula C = QF x 200/10 (where QF = Qubit fluorometer reading, C = 
concentration). 
Protein concentration was also estimated by means of Coomassie stain. Known BSA 
standards of varying concentration were run with total protein on SDS-PAGE and then stained with 
Coomassie. The concentration of total protein was estimated based on the degree of band intensity 
between the known BSA standards and total protein. 
 
4.3.4. Purification of recombinant protein 
4.3.4.1. Small scale purification  
For small-scale protein purification the B-PER
® 
GST Fusion Protein Purification Kit was used. 250 
ml of cells was pelleted by centrifugation at 14 000 rpm for 30 min and the supernatant removed. 
The bacterial pellet was suspended in 10 ml of B-PER reagent and 40 µl of Protease inhibitor by 
vortexing and/or pippeting until a homogeneous cell suspension was attained.  This was followed 
by a centrifugation step at 14 000 rpm for 15 min to separate soluble proteins from insoluble 
proteins and cell debris. The protein of interest in the supernatant was then purified according to 
specification of Thermo Scientific using B-PER
®
 GST Fusion Protein Purification Kit.  
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4.3.4.2. Large scale purification 
After induced bacterial expression, 500 ml of bacterial culture was pelleted by means of 
centrifugation at 14 000 rpm for 30 min. The pellet was resuspended with 2 ml of 1 %Triton and 40 
µl of Protease inhibitor per gram of cell pellet. The pre-cooled cell suspension was lysed using 
sonication followed by centrifugation at 14 000 rpm for 30 min. The cleared lysates was subjected 
to purification according to Promega standards using MagneGST
TM
 protein purification system.   
 
4.3.4.3. GST-pull down assay 
An untagged CypA that was used for GST-pull down assay was purchased from Sigma Aldrich. 
The molecular weight of this protein was verified comparing it with the GST-fusion CypA. This 
was done by cleaving GST-tag from CypA with TEV protease, releasing untagged CypA and 
then ran on SDS PAGE (Results not shown). The cleaved protein molecular weight was 
compared with the purchased CypA on SDS PAGE.  
For particle equilibration, the MagneGST™ Particles were thoroughly re-suspended by 
inverting the bottle several times to obtain a uniform suspension. 20 μl of MagneGST™ particles 
were pipette into a 1.5 ml tube. As a pre-cautionary measure, the MagneGST™ particles were not 
allowed to settle for more than a few minutes during capture of the bait protein as this will reduce 
binding efficiency. The tubes were placed in the magnetic stand and allow the MagneGST™ 
particles to be captured by the magnet and capture typically occurs within a few seconds. From the 
tubes, the supernatant was carefully removed and discarded followed by removal of the tubes from 
the magnetic stand. 250 μl of MagneGST™ Binding/Wash Buffer was added to the particles and 
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re-suspend by pipetting or inverting. Again, the supernatant was removed and discarded. This was 
repeated two more times for total of three washes.  
Following the equilibration of the MagneGST particles, 100 μl of MagneGST™ 
Binding/Wash Buffer was added in order to re-suspend the particles. 30 µg of the GST-fusion 
proteins was added to the MagneGST particles. This was made up to a final volume of 300 μl with 
Radio Immuno Precipitation Assay buffer (50 mM Tris HCl pH 8, 150 mM NaCl, 1% NP-40, and 
0.5 % sodium deoxycholate). This reaction mixture was incubated (with constant gentle mixing) 
for 1 hour at room temperature on a roller. After incubation, the tubes were placed on the magnetic 
stand and allowed the MagneGST™ particles to be captured by the magnet. Once again the 
supernatant was carefully removed but saved for gel analysis. 250 μl of MagneGST™ 
Binding/Wash Buffer was added to the particles and mixed gently. This was then incubated at 
room temperature for 5 min while mixing occasionally by tapping or inverting the tube. The tubes 
were placed in the magnetic stand and allow MagneGST™ particles to be captured by the magnet. 
The supernatant was again removed and saved for analysis of wash. 250 μl of MagneGST™ 
Binding/Wash Buffer was added to the particles and mixed gently by inverting the tube. The tubes 
were again placed on the magnetic stand and allow the MagneGST™ particles to be captured by 
the magnet. Supernant was removed and saved for analysis. This step was repeated for a total of 
three washes. After the last wash, the particles were re-suspended in 20 μl of MagneGST™ 
Binding/ Wash Buffer. A 3–5 μl aliquot was removed for analysis of the efficiency of 
immobilization of the GST-fusion protein or GST control onto the particles. To this aliquot, 20 μl 
1 x SDS loading buffer was added and proteins eluted by boiling for 5 min and then analyzed by 
SDS-PAGE. 
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To each tube of particles carrying GST-fusion protein, GST control and beads 30 μg of 
CypA was added. 155 μl MagneGST™ Binding/Wash Buffer and 20 μl 10 % BSA was added for 
each pull-down reaction, and then incubated overnight (12-16 hours) with gentle mixing at 4 
0
C on 
a roller platform. To remove non-specific adherent proteins, the tubes were briefly vortexed at the 
end of this incubation period. The tubes were placed on a magnetic stand for MagneGST particles 
to be captured. Once again, the supernatant was removed and saved for analysis. To each tube, 400 
μl of MagneGST™ Binding/Wash Buffer was added and mixed gently by inverting the tube. This 
was incubated at room temperature for 5 min while mixing occasionally by tapping or inverting the 
tube. All tubes were placed in the magnetic stand and allow the MagneGST™ particles to be 
captured by the magnet. The supernatant was removed and saved for analysis (it is especially 
important to keep this fraction during initial optimization for troubleshooting purposes). 400 μl of 
MagneGST™ Binding/Wash Buffer was added and mixed gently by inverting the tube. The tubes 
were placed in the magnetic stand and allow the MagneGST™ particles to be captured by the 
magnet. The supernatant was removed and save for analysis. The washing step was repeated for a 
total of three washes. Elution of proteins was done by adding 20 μl of 1 x SDS loading buffer; 
incubate at room temperature for 5 min with occasional mixing. The tubes were placed in the 
magnetic stand and allow the MagneGST™ particles to be captured by the magnet. The eluate was 
removed for analysis. 
 
4.4. RESULTS 
4.4.1. Generation of recombinant plasmid 
The gene specific primers were designed as shown in table 4.1 and 4.2 and then prepared to a 
concentration of 100 ρ.mole/µl. In figure 4.1 below, it is clearly shown that nucleocapsid genes 
 
 
 
 
Chapter 4 
 
88 
 
were successfully amplified. The genes are arranged as follow: SARS-N (1 320 bp), N1 (1 290 bp), 
N2 (620 bp), and N3 (620 bp). The results clearly indicate that all the genes of interest were 
amplified using these gene specific primers and this is evident from figure 4.1. 
 
 
Figure 4.1: Polymerase Chain Reaction of nucleocapsid (N) genes using gene 
specific primers. “M” represents the 100 bp DNA marker with molecular weights 
indicated along the left margin of the figure. Lane 1-4 represents N genes in the 
following order: SARS-N, N1, N2, and N3. 
 
In addition to the polymerase chain reaction (PCR), the presence of the protein coding region was 
verified by means of restriction enzyme digest. Figure 4.2 illustrates the release of the gene from 
the plasmid following its treatment with Sgf1 and Pme1 restriction enzymes. The 4 kbp DNA on 
top of each lane represents the vector, whereas the bottom bands represent the genes of interest. 
From figure 4.2, it is clear that the vector was successfully cleaved at the correct restriction sites 
with the concomitant release of the amplicon.  
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Figure 4.2: pFlexi vector is cleaved with restriction endonuclease Sgf1 and Pme1. “M” 
represents the 100 bp DNA ladder.  Lane 1-4 represents cleaved pFlexi in the following 
order: SARS-N, N1, N2, and N3. The 4 kbp DNA on top of each lane represents the 
vector, whereas the bottom bands represent the genes of interest. 
 
Following the release of the genes from the plasmid, they were re-ligated into the expression vector. 
Successful cloning of the exact protein coding region into vector (pFlexi) was verified by means of 
colony selection and colony PCR subsequent to transformation into KRX competent cells. Figure 
4.3 indicates successful transformation of nucleocapsid genes onto KRX cells with the exception of 
SARS-N, which is shown in figure 4.4. From these figures it is clear that pFlexi was successfully 
cloned and transformed into competent cells.  
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Figure 4.3: Colony PCR confirming the presence of NL63-N genes that have been 
transformed into KRX cells. “M” represents the 100 bp DNA ladder with molecular 
weight indicated along the left margin of the figure. Lane 1-3 represents successful 
transformation of N1/pFlexi. Lane 5-8 represents successful transformation of N2/pFlexi. 
Lane 9-12 represents successful transformation of N3/pFlexi.  
 
Figure 4.4: Colony PCR confirming the presence of SARS N gene that has been 
transformed into KRX competent cells. “M” represent the 100 bp DNA ladder. Lane 1 
and 2 represent the negative control. Lane 3-6 represents successful transformation of 
SARS N/pFlexi.  
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4.4.2. Protein expression and analysis in E. coli cells 
Total proteins were successfully expressed and analyzed using SDS-PAGE, Coomassie blue and 
Western blot. Figure 4.5 represents total proteins that were expressed in a bacterial system. Since 
bacteria express multiple proteins when they undergo their normal metabolic activities, it is 
notable from figure 4.5 by the presence of multiple bands. Moreover, the expression profile of the 
proteins of interests is not distinct in their appearance from the rest of the proteins. All the 
expressed proteins seem to exhibit the same pattern of expression.   
 
Figure 4.5: Coomassie stain showing the lysate of all expressed proteins.  Lane “M” represents 
the protein marker with molecular weight designated along the left margin of the figure. Lane 
1-4 represents nucleocapsid proteins in the following order: SARS-N, N1, N2, and N3.  
 
From the Coomassie brilliant blue results, it was noticed that the presence of the 
nucleocapsid proteins could not be conclusively confirmed. As a result, the cell lysate 
was subjected to Western blotting. All the nucleocapsid proteins were successfully 
detected by means of Western blotting and this is evident in figure 4.6 below.  
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Figure 4.6: Western Blot analysis of nucleocapsid proteins and its trunctaed mutants. On 
the figure, M represents the prestained protein marker. Lane 1-4 represents detected 
proteins in the following order: SARS N, N1, N2, and N3.  
 
The dark band in figure 4.6 indicates the GST-tagged proteins that have been detected in 
nitrocellulose membrane using specific antibodies. From the results it is evident that the 
technique is highly specific to the GST tag that was fused to the protein of interest.  
 
4.4.3. Purification of the recombinant proteins 
The purification of recombinant protein was done using MagneGST protein purification system. 
Following optimization of protein expression the presence of the nucleocapsid proteins was 
confirmed by small-scale purification. The fusion proteins were successfully purified in small scale 
and this is clearly shown in figure 4.7 (A) and (B) below. From the figure below it is clear that the 
proteins were purified at varying concentrations.  
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Figure 4.7: Coomassie stain showing small scale purification of nucleocapsid proteins. (A) 
“M” indicates the protein marker. Lane 1-3 represent purified proteins in the following 
order: N1, N2, and N3 (B): “M” represents the protein marker. Lane 1-3 represents SARS-N, 
N1 and N2.  
 
In figure 4.7(A), it is appreciable that N3 is purified at relatively higher concentrations in 
comparison to N1 and N2, which are indicated in lane 1 and 2, respectively. In figure 4.7(B), on the 
other hand, there are no significant differences in purification levels as seen from the figure.  
 Following the successful purification of all proteins of interest, interaction studies 
between nucleocapsid proteins and CypA were performed by means of GST-pull down assay. From 
figure 4.8, it is clear that there were noticeable signs of interaction between CypA and nucleocapsid 
proteins. Instead, an interesting phenomenon was noticed whereby some proteins were either lost or 
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degraded during the reaction. This is evident in lane 2 and 4 where N1 and N3 disappeared after the 
reaction. In addition, CypA exhibited the same behavior throughout all reactions.  
 
Figure 4.8: Interaction of CypA with nucleocapsid proteins by means of GST-pull down 
assay. “M” represents the protein marker. Lane 1-4 represents protein interactions in the 
following order: SARS-N/CypA, N1/CypA, N2/CypA, and N3/CypA.    
 
4.5. DISCUSSION AND CONCLUSION 
The present study was specifically designed to investigate the interaction of HCoV NL63 
nucleocapsid protein and its truncated mutants with human CypA protein. Using an array of 
molecular techniques, CypA has not been convincingly shown to exhibit a direct and specific 
binding affinity to the nucleocapsid protein. Furthermore, the study intends to reports on the exact 
domain that shows direct and specific interaction with human CypA. However, this will only be 
achieved once the phenomenon that occurred during GST-pull down reaction has been determined.   
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Despite the observed phenomenon in the GST-pull down reaction, the results of the study clearly 
indicate that the proteins of interest were successfully extracted from MCF7 cells and viral RNA, 
amplified by means of RT-PCR and then cloned into a bacterial vector. The latter was verified by 
genome sequencing, transformed into KRX cells and then expressed in a bacterial system. In 
addition, CypA protein was expressed in two different tags viz. GST- and HQ. However, it was 
noticeable that the patterns of expression differ between the two tags hence GST tag was used in 
this study. The explanation for this variation in expression patterns remains obscure. Secondly, it is 
apparent from the results that there is a sharp decline in concentration levels between cell lysates 
and purified protein. This can be attributed to digestion of expressed protein by cell proteases 
merely because CypA is a human protein. Therefore, in a bacterial system it is recognized as 
foreign. The nucleocapsid protein, on the other hand, is a viral protein and is known to be antigenic 
and will thus be destroyed by proteases immediately.  
 The nucleocapsid protein is known to bind to viral RNA and interfere with replication and 
even transcription. CypA, on the other hand, has been shown to be secreted in cells in response to 
inflammatory stimuli and is a potent neutrophil and eosinophil chemo-attractant both in vitro and in 
vivo (Damsker, Bukrinsky et al. 2007). The signaling activity is via CD147 cell surface receptors, 
but the mechanism underlying CypA-mediated signaling and chemotaxis remain obscure. 
Therefore, it is suffice to say that the cross talk between CypA and NL63 nucleocapsid protein 
might play a significant role in the pathogenesis of HCoV NL63. In addition to the above 
mentioned physiological attributes, there is an observed pattern of CypA interaction with an affinity 
for viral capsid proteins. This has been reported for HIV-1 Vpr protein as well as NS5A protein of 
HCV (Zander, Sherman et al. 2003; Chatterji, Lim et al. 2010).  
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Since CypA is engaged in pro-inflammatory reactions, its interaction with nucleocapsid protein 
may lead to a reduced immunological response, paving the way for the virions to replicate 
undisturbed and continuously. In addition to its obscure role in immunological reaction, the 
observed pattern of CypA interaction with capsid proteins may provide clues to its exact role in a 
myriad of viral infections. It may be possible that CypA has a stereochemical active site for capsid 
proteins enabling it to interact with such proteins. Therefore, binding of CypA to capsid proteins 
may result in conformational changes in the structure of CypA, which will then render it inactive 
from performing its normal physiological pro-inflammatory role. Therefore, determination of this 
site and its conformation may provide clues to the development of therapeutic strategies.  
 In conclusion, the interaction of CypA with nucleocapsid protein needs to be determined. 
Most importantly, the stereochemically active site of CypA with capsid proteins also needs to be 
determined. Given the normal physiological functions of CypA, HCoV NL63 could be evading the 
immune response via suppression of inflammatory mediators thus leading to disease progression. 
Nonetheless, there is still a need to fully comprehend other functional significances of these 
interactions in the entire pathophysiological process of HCoV NL63. Hopefully, once this 
phenomenon between the two proteins has been ascertained, this will shed light in order to fully 
comprehend the infectious process and also provide hints for better understanding of a possible 
infection pathway.  
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Summary 
The history of coronaviruses began in 1959 and this group of viruses was officially accepted as a 
genus in 1960 (Kapikian 1975). The human and animal coronaviruses were segregated into three 
groups based on their antigenic and genetic make-up. The human coronavirus infection was 
usually not associated with severe diseases, but following the severe acute respiratory syndrome 
(SARS) epidemic in 2002 it became evident that highly pathogenic strains can still evolve. Most 
recently, Lia van der Hoek et al. (2004) reported the discovery of human coronavirus (HCoV) 
NL63 from a 7 month old girl with coryza, conjunctivitis, fever, and bronchilitis. The 
pathophysiology of this novel virus still remains to be determined. Some scientists believe that it is 
through the interaction of viral structural proteins with host cell proteins. Amongst these structural 
proteins, the nucleocapsid (N) protein has been reported to be highly antigenic and is associated 
with several host cell interactions (Zhou, Liu et al. 2008). Luo et al (2004) has shown SARS-N to 
interact with human cyclophilin A (CypA). The latter is a peptidyl-prolyl cis/trans isomerase 
(PPIA) that is involved in cellular signaling events. It has also been shown to be secreted in cells in 
response to inflammatory stimuli and is a potent neutrophil and eosinophil chemo-attractant (Yang, 
Lu et al. 2008). Most importantly, CypA has been demonstrated to play a critical role in 
pathogenesis of viruses such as human immune virus (HIV)-1, hepatitis C virus (HCV), and 
SARS. Therefore, determination of host and viral protein interactions is crucial for elucidation of 
strategies for therapeutic intervention. Using an array of molecular and computational techniques, 
these studies aimed at determing these interactions and most importantly identify the exact 
nucleocapsid protein domains that are responsible.  
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Initially, bioinformatic tools were applied in order to predict the function HCoV NL63-N gene and 
protein. SARS-N is known to interact with CypA, therefore comparing its properties with HCoV 
NL63-N will enable one to infer the unknown function NL63-N protein. This study has shown that 
HCoV NL63-N exhibits some degree of homology to SARS-N. However, these proteins exhibit 
slightly different characteristics in terms of their post-translational modifications. From this 
evidence of evolutionary relationship between the two strains, it is reasonable to assume that 
NL63-N protein will interact with CypA.  
Following the prediction of NL63-N function, CypA was cloned and expressed in a 
bacterial system for interaction with HCoV NL63-N protein. Initially, CypA gene was extracted 
from MCF7 cells and then amplified using reverse transcription polymerase chain reaction (RT-
PCR) into multiple genes. The latter was cloned into a sequencing vector and later shuttled into a 
bacterial expression vector following the confirmation of the correct protein coding region. The 
cloned vector was transformed into KRX cells and protein expression induced by addition of 
isopropyl β-D-1-thiogalactopyranoside (IPTG). The protein of interest was detected from the cell 
lysate by means of Western blotting followed by purification using MagneGST protein purification 
system.  
The nucleocapsid was also cloned and expressed in a bacterial system. Following 
expression, the proteins were detected and then purified under the conditions described for CypA. 
Interaction studies between CypA and N proteins were conducted using the GST-pull down assay. 
However, these interactions could not be convincingly demonstrated to be direct and specific. 
Therefore, the interaction conditions need to be optimized. Initially, the protein concentrations 
need to be increased into desirable levels, so as to increase the chances of interaction. Lastly, the 
stringency of the buffers needs to be optimized so that they do not interfere with protein activity.  
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APPENDIX 1 
Summary of procedures used 
Polymerase Chain Reaction 
This reaction was carried out in using the cDNA library obtained using reverse transcription 
technique. The purpose of this reaction is to make multiple copies of a particular gene. This is 
essential in order to acquire enough starting template for subsequent experimental procedures. 
There are 3 major steps in a polymerase chain reaction (PCR): denaturation, annealing, and 
extension. These are repeated for 30 or 40 cycles in an automated thermocycler.  
The initial phase involves melting of the double stranded (ds) DNA into single stranded 
(ss) DNA followed by annealing of primers and formation of stable ionic bonds between primers 
and DNA. The reaction is completed with attachment of Taq polymerase on the template and the 
extension of the gene of interest.  
 
Cloning into vectors 
DNA cloning is a technique for reproducing DNA fragments. It allows a copy of any specific part 
of a DNA sequence to be selected among many others and produced in an unlimited amount. The 
cloning strategy involves 3 steps. The first step is digestion of DNA sample with restriction enzyme 
followed by digestion of DNA plasmid vector with the same restriction enzyme. Lastly, the DNA 
sample is ligated into the plasmid vector.  
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This diagram represents the vectors that were used to clone the genes of interest. The 
figure marked “A” indicates PGEM-T Easy cloning vector. The latter was chosen 
because of its convenience for cloning PCR products. The vector provides several 
options for the removal of the DNA insert with a single restriction enzyme. In this 
study, EcoR1 was chosen as the restriction enzyme. The figure marked “B”, on the 
other hand, represents the GST tagged bacterial expression vector that is appended by 
Sgf1 and Pme1 restriction sites. The T7 promoter upstream controls the expression of 
the DNA insert.  
 
Transformation into competent cells 
Transformation is used to transfer exogenous DNA into cells. It is one of the three processes by 
which exogenous genetic material may be introduced into a bacterial cell. The method involves 
incubation of competent cells with the DNA on ice and then briefly heat shock (42
o
C for 45 sec.) 
thus allowing the DNA to enter the cells. Because the plasmid vector contains an origin of 
replication, it can replicate independent of the cell. The selection of transformed cells is performed 
on agar plates supplemented with an antibiotic together with X-gal. This technique is based on the 
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following principle. In transformed cells, the lacZ gene found on the plasmid vector is disrupted 
because of the insertion of the gene of interest within the lacZ code. As a result, the plasmid is 
unable to express lacZ-alpha subunit. Conversely, in untransformed cells the lacZ gene is still 
intact; hence there is expression of lacZ-alpha subunit and production of a functional ß-
galactosidase. Essentially, the white appearance of transformed cells on agar plates is due to the 
inability to express ß-galactosidase. The blue color of untransformed cells, on the other hand, is due 
to the action of ß-galactosidase on X-gal that is supplemented on the agar plate.  
 
Protein expression 
This technique is used to translate recombinant protein by manipulating the bacterial system. The 
target DNA that is inserted onto the plasmid vector is under the control of T7 promoter. The 
transcription of the lac operon is triggered by isopropyl β-D-1-thiogalactopyranoside (IPTG).  
 
SDS PAGE 
The sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) technique is used to 
separate proteins according to their electrophoretic ability, posttranslational modifications and other 
factors. The protein complexes are separated according to size by means of SDS PAGE. The 
procedure involves mixing of the protein complex to be analyzed with SDS. The latter is an anionic 
detergent which denatures secondary and non-disulfide-linked tertiary proteins, and applies a 
negative charge to each protein in proportion to its mass. This is important because different 
proteins with similar molecular weight would migrate differently due to differences in mass charge.  
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This represents the apparatus used in SDS PAGE analysis as shown on the left hand 
side. The illustration on the right indicates the principle of the technique. Total 
proteins are separated according to their electrophoretic ability into different 
molecular weight.  
 
The following parameters should be kept in check when performing electrophoresis: strength of the 
electric field, viscosity and temperature of the medium in which the molecules are moving. These 
are crucial as they influence the rate of migration of charged molecules in a solution in response to 
electric field.    
 
Western blot  
The Western blot or immunoblot is used to detect the specific protein of interest. This analytical 
technique involves the immobilization of protein on membrane nitrocellulose, and then followed by 
detection using monoclonal or polyclonal antibody. Western blot detects the specific protein, 
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whereas SDS-PAGE provides information about the molecular weight and the potential existence of 
different isoforms of the protein under study.   
 
The protein of interest is indicated with the red triangle on nitrocellulose membrane. 
This protein is initially bound to a primary which in turn binds to a secondary antibody 
that is covalently attached to an enzyme conjugate. The presence of the protein is 
detected by addition of a chromogenic substrate which illuminates a purple color when 
it reacts with secondary antibody.  
 
GST-pull down assay 
In the cyctoplamic and membrane compartments of the cell, there is an extensive network of 
protein- protein interactions that take place. A preliminary step in understanding protein structure 
and function is to determine which proteins interact with each other, thereby identifying the 
relevant biological pathways. In this system, the protein of interest is fused with a glutathione-S-
transferase (GST) tag that is incorporated upstream into an expression vector. Induction of protein 
expression from the vector′s promoter results in expression of a fusion protein. Since the 
expression process involves transcription and translation of even housekeeping genes, the system 
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is used to specifically purify and detect proteins of interest from a myriad of host cytoplasmic and 
membrane proteins. This GST-fusion protein can then be purified from cells via its high affinity 
for glutathione. 
 
APPENDIX 2 
SARS-N gene 
ATGGCTAGTGTAAATTGGGCCGATGACAGAGCTGCTAGGAAGAAATTTCCTCCTCCTTC
ATTTTACATGCCTCTTTTGGTTAGTTCTGATAAGGCACCATATAGGGTCATTCCCAGGA
ATCTTGTCCCTATTGGTAAGGGTAATAAAGATGAGCAGATTGGTTATTGGAATGTTCAA
GAGCGTTGGCGTATGCGCAGGGGGCAACGTGTTGATTTGCCTCCTAAAGTTCATTTTTA
TTACCTAGGTACTGGACCTCATAAGGACCTTAAATTCAGACAACGTTCTGATGGTGTTG
TTTGGGTTGCTAAGGAAGGTGCTAAAACTGTTAATACCAGTCTTGGTAATCGCAAACGT
AATCAGAAACCTTTGGAACCAAAGTTCTCTATTGCTTTGCCTCCAGAGCTCTCTGTTGT
TGAGTTTGAGGATCGCTCTAATAACTCATCTCGTGCTAGCAGTCGTTCTTCAACTCGTA
ACAACTCACGAGACTCTTCTCGTAGCACTTCAAGACAACAGTCTCGCACTCGTTCTGAT
TCTAACCAGTCTTCTTCAGATCTTGTTGCTGCTGTTACTTTGGCTTTAAAGAACTTAGGT
TTTGATAACCAGTCGAAGTCACCTAGTTCTTCTGGTACTTCCACTCCTAAGAAACCTAA
TAAGCCTCTTTCTCAACCCAGGGCTGATAAGCCTTCTCAGTTGAAGAAACCTCGTTGGA
AGCGTGTTCCTACCAGAGAGGAAAATGTTATTCAGTGCTTTGGTCCTCGTGATTTTAAT
CACAATATGGGGGATTCAGATCTTGTTCAGAATGGTGTTGATGCCAAAGGTTTTCCACA
GCTTGCTGAATTGATTCCTAATCAGGCTGCGTTATTCTTTGATAGTGAGGTTAGCACTG
ATGAAGTGGGTGATAATGTTCAGATTACCTACACCTACAAAATGCTTGTAGCTAAGGA
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TAATAAGAACCTTCCTAAGTTCATTGAGCAGATTAGTGCTTTTACTAAACCCAGTTCTA
TCAAAGAAATGCAGTCACAATCATCTCATGTTGCTCAGAACACAGTACTTAATGCTTCT
ATTCCAGAATCTAAACCATTGGCTGATGATGATTCAGCCATTATAGAAATTGTCAACGA
GGTTTTGCATTAA 
 
NL63-N gene 
ATGTCTGATAATGGACCCCAATCAAACCAACGTAGTGCCCCCCGCATTACATTTGGTGG
ACCCACAGATTCAACTGACAATAACCAGAATGGAGGACGCAATGGGGCAAGGCCAAA
ACAGCGCCGACCCCAAGGTTTACCCAATAATACTGCGTCTTGGTTCACAGCTCTCACTC
AGCATGGCAAGGAGGAACTTAGATTCCCTCGAGGCCAGGGCGTTCCAATCAACACCAA
TAGTGGTCCAGATGACCAAATTGGCTACTACCGAAGAGCTACCCGACGAGTTCGTGGT
GGTGACGGCAAAATGAAAGAGCTCAGCCCCAGATGGTACTTCTATTACCTAGGAACTG
GCCCAGAAGCTTCACTTCCCTACGGCGCTAACAAAGAAGGCATCGTATGGGTTGCAAC
TGAGGGAGCCTTGAATACACCCAAAGACCACATTGGCACCCGCAATCCTAATAACAAT
GCTGCCACCGTGCTACAACTTCCTCAAGGAACAACATTGCCAAAAGGCTTCTACGCAG
AGGGAAGCAGAGGCGGCAGTCAAGCCTCTTCTCGCTCCTCATCACGTAGTCGCGGTAA
TTCAAGAAATTCAACTCCTGGCAGCAGTAGGGGAAATTCTCCTGCTCGAATGGCTAGC
GGAGGTGGTGAAACTGCCCTCGCGCTATTGCTGCTAGACAGATTGAACCAGCTTGAGA
GCAAAGTTTCTGGTAAAGGCCAACAACAACAAGGCCAAACTGTCACTAAGAAATCTGC
TGCTGAGGCATCTAAAAAGCCTCGCCAAAAACGTACTGCCACAAAACAGTACAACGTC
ACTCAAGCATTTGGGAGACGTGGTCCAGAACAAACCCAAGGAAATTTCGGGGACCAA
GACCTAATCAGACAAGGAACTGATTACAAACATTGGCCGCAAATTGCACAATTTGCTC
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CAAGTGCCTCTGCATTCTTTGGAATGTCACGCATTGGCATGGAAGTCACACCTTCGGGA
ACATGGCTGACTTATCATGGAGCCATTAAATTGGATGACAAAGATCCACAATTCAAAG
ACAACGTCATACTGCTGAACAAGCACATTGACGCATACAAAACATTCCCACCAACAGA
GCCTAAAAAGGACAAAAAGAAAAAGACTGATGAAGCTCAGCCTTTGCCGCAGAGACA
AAAGAAGCAGCCCACTGTGACTCTTCTTCCTGCGGCTGACATGGATGATTTCTCCAGAC
AACTTCAAAATTCCATGAGTGGAGCTTCTGCTGATTCAACTCAGGCATAA 
 
229E-N gene 
ATGGCTACAGTCAAATGGGCTGATGCATCTGAACCACAACGTGGTCGTCAGGGTAG
AATACCTTATTCTCTTTATAGCCCTTTGCTTGTTGATAGTGAACAACCTTGGAAGGTG
ATACCTCGTAATTTGGTACCCATCAACAAGAAAGACAAAAATAAGCTTATAGGCTAT
TGGAATGTTCAAAAACGTTTCAGAACTAGAAAGGGCAAACGGGTGGATTTGTCACC
CAAGCTGCATTTTTATTATCTTGGCACAGGACCCCATAAAGATGCAAAATTTAGAGA
GCGTGTTGAAGGTGTCGTCTGGGTTGCTGTTGATGGTGCTAAAACTGAACCTACAGG
TTACGGTGTTAGGCGCAAGAATTCAGAACCAGAGATACCACACTTCAATCAAAAGC
TCCCAAATGGTGTTACTGTTGTTGAAGAACCTGACTCCCGTGCTCCTTCCCGGTCTCA
GTCGAGGTCGCAGAGTCGCGGTCGTGGTGAATCCAAACCTCAATCTCGGAATCCTTC
AAGTGACAGAAACCATAACAGTCAGGATGACATCATGAAGGCAGTTGCTGCGGCTC
TTAAATCTTTAGGTTTTGACAAGCCTCAGGAAAAAGATAAAAAGTCAGCGAAAACG
GGTACTCCTAAGCCTTCTCGTAATCAGAGTCCTGCTTCTTCTCAAACTTCTGCCAAGA
GTCTTGCTCGTTCTCAGAGTTCTGAAACAAAAGAACAAAAGCATGAAATGCAAAAG
CCACGGTGGAAAAGACAGCCTAATGATGATGTGACATCTAATGTCACACAATGTTTT
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GGCCCCAGAGACCTTGACCACAACTTTGGAAGTGCAGGTGTTGTGGCCAATGGTGTT
AAAGCTAAAGGCTATCCACAATTTGCTGAGCTTGTGCCGTCAACAGCTGCTATGCTG
TTTGATAGTCACATTGTTTCCAAAGAGTCAGGCAACACTGTGGTCTTGACTTTCACTA
CTAGAGTGACTGTGCCCAAAGACCATCCACACTTGGGTAAGTTTCTTGAGGAGTTAA
ATGCATTCACTAGAGAAATGCAACAACATCCTCTTCTTAACCCTAGTGCACTAGAAT
TCAACCCATCTCAAACTTCACCTGCAACTGCTGAACCAGTGCGTGATGAAGTTTCTA
TTGAAACTGACATAATTGATGAAGTAAACTAA 
 
OC43-N gene 
ATGTCTTTTACTCCTGGTAAGCAATCCAGTAGTAGAGCGTCCTCTGGAAATCGTTCT
GGTAATGGCATCCTCAAGTGGGCCGATCAGTCCGACCAGTTTAGAAATGTTCAAACC
AGGGGTAGAAGAGCTCAACCCAAGCAAACTGCTACCTCTCAGCAACCATCAGGAGG
GAATGTTGTACCCTACTATTCTTGGTTCTCTGGAATTACTCAGTTTCAAAAGGGAAA
GGAGTTTGAGTTTGTAGAAGGACAAGGTGTGCCTATTGCACCAGGAGTCCCAGCTAC
TGAAGCTAAGGGGTACTGGTACAGACACAACAGACGTTCTTTTAAAACAGCCGATG
GCAACCAGCGTCAACTGCTGCCACGATGGTATTTTTACTATCTGGGAACAGGACCGC
ATGCTAAAGACCAGTACGGCACCGATATTGACGGAGTCTACTGGGTCGCTAGCAAC
CAGGCTGATGTCAATACCCCGGCTGACATTGTCGATCGGGACCCAAGTAGCGATGA
GGCTATTCCGACTAGGTTTCCGCCTGGCACGGTACTCCCTCAGGGTTACTATATTGA
AGGCTCAGGAAGGTCTGCTCCTAATTCCAGATCTACTTCGCGCACATCCAGCAGAGC
CTCTAGTGCAGGATCGCGTAGTAGAGCCAATTCTGGCAATAGAACCCCTACCTCTGG
TGTAACACCTGACATGGCTGATCAAATTGCTAGTCTTGTTCTGGCAAAACTTGGCAA
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GGATGCCACTAAACCTCAGCAAGTAACTAAGCATACTGCCAAAGAAGTCAGACAGA
AAATTTTGAATAAGCCCCGCCAGAAGAGGAGCCCCAATAAACAATGCACTGTTCAG
CAGTGTTTTGGTAAGAGAGGCCCTAATCAGAATTTTGGTGGTGGAGAAATGTTAAAA
CTTGGAACTAGTGACCCACAGTTCCCCATTCTTGCAGAACTCGCACCCACAGCTGGT
GCGTTTTTCTTTGGATCAAGATTAGAGTTGGCCAAAGTGCAGAATTTATCTGGGAAT
CCTGACGAGCCCCAGAAGGATGTTTATGAATTGCGCTATAACGGCGCAATTAGGTTT
GACAGTACACTTTCAGGTTTTGAGACCATAATGAAGGTGCTGAATGAGAATTTGAAT
GCCTATCAACAACAAGATGGTATGATGAATATGAGTCCAAAACCACAGCGTCAGCG 
TGGTCATAAGAATGGACAAGGAGAAAATGATAATATAAGTGTTGCAGTGCCCAAAA
GCCGCGTGCAGCAAAATAAGAGTAGAGAGTTGACTGCAGAGGACATCAGCCTTCTT
AAGAAGATGGATGAGCCCTATACTGAAGACACCTCAGAAATATAA 
 
Feline CoV-N gene 
ATGGCCACACAGGGACAACGCGTCAACTGGGGAGATGAACCTTCCAAAAGACGCAG
TCGTTCTAACTCTCGTGGTCGGAAGAATAATGATATACCTTTGTCTTACTTCAACCCC
CTCACCCTCGAATCAGGATCAAAGTTTTGGAATGTATGTCCGAGAGACTTTGTTCCC
AAGGGAATAGGTAACAAGGATCAACAAATTGGTTATTGGAATAGACAGTTACGCTA
CCGAATTGTCAAGGGCCAGCGTAAGGAACTGCCTGAGAGATGGTTCTTCTACTATCT
AGGCACAGGACCTCATGCTGATGCTAAATTTAAAGACAAGATTGATGGAGTCTTCTG
GGTTGCTAGGGATGGTGCCATGAACAAGCCTACAACACTAGGCACTCGTGGAACCA
ATAATGAATCCAAACCTTTGAAATTTGATGGTAAGATACCACCACAATTTCAGCTTG
AAGTGAATCGTTCTAGAAACAATTCAAGAGCAGGTTCTCAGTCTAGATCAACCTCAA
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GAAATAGGTCTCAATCTAGAGGAAGACAACAATCCAATAACCAGAACGATAATGTT
GAGGATACAATTGTTGCTGTGCTTCAAAGATTAGGTGTTACTGATAAGCAAAGGTCA
CGTTCTAAATCCAGAGAACGTAGTGATTCCAAGCCTAGGGATACAACACCTAAAAA
TTCCAACAAACACACATGGAAGAAAACTGCAGGTAAGGGAGATGTGACAAATTTCT
ATGGTGCTAGAAGTGCTTCAGCTAACTTTGGTGATAGTGATCTCGTTGCCAATGGTA
ACGCTGCCAAATGCTACCCTCAGATAGCTGAATGCGTTCCATCAGTATCTAGCATGC
TCTTCGGCAGTCAATGGTCTGCTGAAGAAGCTGGTGATCAAGTGAAAGTCACGCTCA
CTCATACTTACTACCTGCCAAAGGATGATGCCAAAACCAGTCAGTTCCTAGAACAGA
TTGACGCCTACAAACGGCCTTCACAGGTGGCTAAAGGTCAGAGGACAAGGAAATCC
CGCTCTAAGTCTGCTGATAAGAAGCCTGAGGAATTGTCTGTAACTCTTGTAGAGGCA
TACACAGATGTGTTTGATGACACACAGGTTGAGATGATTGATGAGGTTACGAACTAA 
 
TGEV-N gene 
ATGGCCAACCAGGGACAACGTGTCAGTTGGGGAGATGAATCTACCAAAACACGTGG
TCGCTCCAATTCCCGTGGTCGGAAGAGTAATAACATACCTCTTTCATTCTTCAACCCC
ATAACCCTCCAGCAAGGTTCAAAATTTTGGAACTTATGTCCGAGGGACTTTGTACCC
AAAGGAATAGGTAACAGGGATCAACAGATTGGTTATTGGAATAGACAAACTCGCTA
TCGCATGGTGAAGGGCCAACGTAAAGAGCTTCCTGAAAGGTGGTTCTTCTACTACTT
AGGTACTGGACCTCATGCAGATGCCAAATTTAAAGATAAATTAGATGGAGTTGTCTG
GGTTGCCAAGGATGGTGCCATGAACAAACCAACCACGCTTGGTAGTCGTGGTGCTA
ATAATGAATCCAAAGCTTTGAAATTCGATGGTAAAGTGCCAGGCGAATTTCAACTTG
AAGTTAACCAGTCAAGGGATAATTCAAGGTCACGCTCACAATCTAGATCTCGGTCTA
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GAAACAGATCTCAATCTAGAGGCAGGCAACAATCCAATAACAAGAAGGATGACAGT
GTAGAACAAGCTGTTCTTGCCGCACTTAAAAAGTTAGGTGTTGACACAGAAAAACA
ACAGCAACGCTCTCGTTCTAAATCTAAAGAACGTAGTAACTCTAAGACAAGAGATA
CTACACCTAAGAATGAAAACAAACACACCTGGAAGAGAACTGCAGGTAAAGGTGAT
GTGACAAGATTTTATGGAGCTAGAAGCAGTTCAGCCAATTTTGGTGACAGTGACCTC
GTTGCCAATGGGAGCAGTGCCAAGCATTACCCACAATTGGCTGAATGTGTTCCATCT
GTGTCTAGCATTTTGTTTGGAAGCTATTGGACTTCAAAGGAAGATGGCGACCAGATA
GAAGTCACGTTCACACACAAATACCACTTGCCAAAGGATGATCCTAAAACTGAACA
ATTCCTTCAGCAGATTAATGCCTATGCTCGCCCATCAGAAGTGGCAAAAGAACAGA
GAAAAAGAAAATCTCGTTCTAAATCTGCAGAAAGGTCAGAGCAAGAGGTGGTACCT
GATGCATTAATAGAAAATTATACAGATGTGTTTGATGACACACAGGTTGAGATGATT
GATGAGGTAACGAACTAA 
 
Bovine CoV-N gene 
ATGTGAGCGATTGCGTGCGTGCATCCGCTTCACTGATCTCTTGTTAGATCTTTTTATA
ATCTAAACTTTAAGGATGTCTTTTACTCCTGGTAAGCAATCCAGTAGTAGAGCGTCC
TCTGGAAATCGTTCTGGTAATGGCATCCTTAAGTGGGCCGATCAGTCCGACCAATCT
AGAAATGTTCAAACCAGGGGTAGAAGAGCTCAACCCAAGCAAACTGCTACTTCTCA
GCAACCATCAGGAGGGAATGTTGTACCCTACTATTCTTGGTTCTCTGGAATTACTCA
GTTTCAAAAGGGAAAGGAGTTTGAATTTGCTGAGGGACAAGGTGTGCCTATTGCAC
CAGGAGTCCCAGCTACTGAAGCTAAGGGGTACTGGTACAGACACAACAGACGTTCT
TTTAAAACACGCGATGGCAACCAGCGTCAATTGCTGCCACGATGGTATTTTTACTAT
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CTTGGAACAGGACCGCATGCCAAAGACCAGTATGGCACCGACATTGACGGAGTCTT
CTGGGTCGCTAGTAACCAGGCTGATGTCAATACCCCGGCTGACATTCTCGATCGGGA
CCCAAGTAGCGATGAGGCTATTCCGACTAGGTTTCCGCCTGGCACGGTACTCCCTCA
GGGTTACTATATTGAAGGCTCAGGAAGGTCTGCTCCTAATTCCAGATCTACTTCACG
CGCATCCAGTAGAGCCTCTAGTGCAGGATCGCGTAGTAGAGCCAATTCTGGCAATA
GAACCCCTACCTCTGGTGTAACACCTGATATGGCTGATCAAATTGTCAGTCTTGTTTT
GGCAAAACTTGGCAAGGATGCCACTAAGCCACAGCAAGTAACTAAGCAGACTGCCA
AAGAAATCAGACAGAAAATTTTGAATAAGCCCCGCCAGAAGAGGAGCCCCAATAAA
CAATGCACTGTTCAGCAGTGTTTTGGGAAGAGAGGCCCCAATCAGAATTTTGGTGGT
GGAGAAATGTTAAAACTTGGAACTAGTGACCCACAGTTCCCCATTCTTGCAGAACTC
GCACCCACAGCTGGTGCGTTTTTCTTTGGATCAAGATTAGAGTTGGCCAAAGTGCAG
AATTTGTCTGGGAATCTTGATGAGCCCCAGAAGGATGTTTATGAATTACGCTACAAT
GGCGCAATTAGATTTGATAGTACACTTTCAGGTTTTGAGACCATAATGAAGGTGTTG
AATGAGAATTTGAATGCATATCAACAACAAGATGGTATGATGAATATGAGTCCAAA
ACCACAGCGTCAGCGTGGTCAGAAGAATGGACAAGGAGAAAATGATAATATAAGTG
TTGCAGCGCCCAAAAGCCGTGTGCAGCAAAATAAGAGTAGAGAGTTGACTGCAGAG
GACATCAGCCTTCTTAAGAAGATGGATGAGCCCTATACTGAAGACACCTCAGAAAT
ATAAGAGAATGAACCTTATGTCGGTACCTGGTGGCAACCCCTCGCAGGAAAGTCGG
GATAAGGCATTCTCTATCAGAATGGATGTCTTGCTGCTATAATAGATAGAGAAGGTT
ATAGCAGACTATAGATTAATTAGTTGAAAGTTTTGTGTGGTAATGTATAGTGTTGGA
GAAAGTGAAAGACTTGCGGAAGTAATTGCCCACAAGTGCCCAAGGGGAAGAGCCA
GCATGTTAAGTTGCCACCCAGTAATTAGTAAATGAATGAAGTTAATTATGGCCAATT
GGAAGAATCACA 
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Murine hepatitis virus-N gene 
ATGTCTTTTGTTCCTGGGCAAGAAAATGCCGGTAGCAGAAGCTCCTCTGGAAACCGC
GCTGGTAATGGCATCCTCAAGAAGACCACTTGGGCTGACCAAACCGAGCGTGGAAA
TAGAGGCAGAAGGAACCATCCCAAGCAGACTGCAACTACTCAGCCCAATGCCGGGA
GTGTGGTTCCCCATTACTCTTGGTTTTCGGGCATCACCCAGTTTCAAAAGGGAAAGG
AGTTCCAGTTTGCACAAGGACAGGGAGTGCCTATTGCCAGTGGAATCCCCGCTTCAG
AGCAAAAGGGATATTGGTATAGACACAACCGACGTTCTTTTAAAACACCTGATGGC
CAGCACAAGCAGCTACTGCCCAGATGGTATTTTTACTATCTTGGAACAGGGCCCCAT
GCTGGCGCAGAGTATGGCGACGATATCGAAGGAGTTGTCTGGGTCGCAAGCCAACA
GGCCGACACTAAGACCACTGCCGATGTTGTTGAAAGGGACCCAAGCAGTCATGAGG
CTATTCCTACTAAGTTTGCGCCCGGCACGGTATTGCCTCAAGGCTTTTATGTAGAAG
GCTCGGGAAAGTCTGCACCTGCTAGTCGATCTGGTTCGCGGTCACAATCCCGTGGGC
CAAATAATCGCGCTAGAAGCAGTTCCAACCAGCGCCAGCCTGCCTCTGCTGTAAAA
CCTGACATGGCCGAAGAAATTGCTGCTCTTGTTTTGGCTAAGCTTGGTAAAGATGCC
GGCCAGCCCAAGCAGGTAACTAAGCAAAGCGCCAAAGAAGTCAGGCAGAAAATTTT
AACTAAGCCTCGTCAAAAGAGGACTCCAAACAAGCAGTGCCCAGTGCAGCAGTGTT
TTGGGAAGAGAGGCCCTAATCAGAACTTTGGAGGCTCTGAAATGTTAAAACTTGGA
ACTAGTGATCCGCAGTTCCCCATTCTTGCAGAGTTGGCTCCAACACCTAGTGCCTTCT
TCTTTGGATCTAAATTAGAATTGGTCAAAAAGAACTCTGGTGGTGCTGATGAACCCA
CCAAAGATGTTTATGAATTGCAGTATTCAGGTGCAATTAGATTTGATAGTACTCTAC
CCGGTTTTGAGACTATCATGAAAGTGTTGACTGAGAATTTGAATGCCTACCAGGACC
AAGCTGGTAGTGTAGATCTAGTGAGCCCAAAGCCTCCAAGAAGAGGTCGTAGACAG
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GCTCAAGAAAAGAAAGATGAAGTAGATAATGTAAGCGTTGCAAAGCCCAAAAGCTT
GGTGCAGCGAAATGTAAGTAGAGAATTAACCCCCGAGGATCGTAGCCTGCTGGCTC
AGATCCTAGACGATGGCGTTGTGCCAGATGGGTTGGAAGATGACTCTAATGTGTAA 
 
SARS-N amino acid sequence 
MASVNWADDRAARKKFPPPSFYMPLLVSSDKAPYRVIPRNLVPIGKGNKDEQIGYWNV
QERWRMRRGQRVDLPPKVHFYYLGTGPHKDLKFRQRSDGVVWVAKEGAKTVNTSLG
NRKRNQKPLEPKFSIALPPELSVVEFEDRSNNSSRASSRSSTRNNSRDSSRSTSRQQSRTR
SDSNQSSSDLVAAVTLALKNLGFDNQSKSPSSSGTSTPKKPNKPLSQPRADKPSQLKKPR
WKRVPTREENVIQCFGPRDFNHNMGDSDLVQNGVDAKGFPQLAELIPNQAALFFDSEV
STDEVGDNVQITYTYKMLVAKDNKNLPKFIEQISAFTKPSSIKEMQSQSSHVAQNTVLN
ASIPESKPLADDDSAIIEIVNEVLH 
 
NL63-N amino acid sequence 
MSDNGPQSNQRSAPRITFGGPTDSTDNNQNGGRNGARPKQRRPQGLPNNTASWFTALT
QHGKEELRFPRGQGVPINTNSGPDDQIGYYRRATRRVRGGDGKMKELSPRWYFYYLGT
GPEASLPYGANKEGIVWVATEGALNTPKDHIGTRNPNNNAATVLQLPQGTTLPKGFYAE
GSRGGSQASSRSSSRSRGNSRNSTPGSSRGNSPARMASGGGETALALLLLDRLNQLESK
VSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKQYNVTQAFGRRGPEQTQGNFGDQD
LIRQGTDYKHWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYHGAIKLDDKDPQFKDN
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VILLNKHIDAYKTFPPTEPKKDKKKKTDEAQPLPQRQKKQPTVTLLPAADMDDFSRQLQ
NSMSGASADSTQ 
 
229E-N amino acid sequence 
YSPLLVDSEQPWKVIPRNLVPINKKDKNKLIGYWNVQKRFRTRKGKRVDLSPKLHFYYL
GTGPHKDAKFRERVEGVVWVAVDGAKTEPTGYGVRRKNSEPEIPHFNQKLPNGVTVVE
EPDSRAPSRSQSRSQSRGRGESKPQSRNPSSDRNHNSQDDIMKAVAAALKSLGFDKPQE
KDKKSAKTGTPKPSRNQSPASSQTSAKSLARSQSSETKEQKHEMQKPRWKRQPNDDVT
SNVTQCFGPRDLDHNFGSAGVVANGVKAKGYPQFAELVPSTAAMLFDSHIVSKESGNT
VVLTFTTRVTVPKDHPHLGKFLEELNAFTREMQQHPLLNPSALEFNPSQTSPATAEPVRD
EVSIETDIIDEVN 
 
OC43-n amino acid sequence 
MSFTPGKQSSSRASSGNRSGNGILKWADQSDQFRNVQTRGRRAQPKQTATSQQPSGGN
VVPYYSWFSGITQFQKGKEFEFVEGQGVPIAPGVPATEAKGYWYRHNRRSFKTADGNQ
RQLLPRWYFYYLGTGPHAKDQYGTDIDGVYWVASNQADVNTPADIVDRDPSSDEAIPT
RFPPGTVLPQGYYIEGSGRSAPNSRSTSRTSSRASSAGSRSRANSGNRTPTSGVTPDMAD
QIASLVLAKLGKDATKPQQVTKHTAKEVRQKILNKPRQKRSPNKQCTVQQCFGKRGPN
QNFGGGEMLKLGTSDPQFPILAELAPTAGAFFFGSRLELAKVQNLSGNPDEPQKDVYEL
RYNGAIRFDSTLSGFETIMKVLNENLNAYQQQDGMMNMSPKPQRQRGHKNGQGENDN
ISVAVPKSRVQQNKSRELTAEDISLLKKMDEPYTEDTSEI 
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Feline CoV-N amino acid sequence 
MATQGQRVNWGDEPSKRRSRSNSRGRKNNDIPLSYFNPLTLESGSKFWNVCPRDFVPK
GIGNKDQQIGYWNRQLRYRIVKGQRKELPERWFFYYLGTGPHADAKFKDKIDGVFWV
ARDGAMNKPTTLGTRGTNNESKPLKFDGKIPPQFQLEVNRSRNNSRAGSQSRSTSRNRS
QSRGRQQSNNQNDNVEDTIVAVLQRLGVTDKQRSRSKSRERSDSKPRDTTPKNSNKHT
WKKTAGKGDVTNFYGARSASANFGDSDLVANGNAAKCYPQIAECVPSVSSMLFGSQW
SAEEAGDQVKVTLTHTYYLPKDDAKTSQFLEQIDAYKRPSQVAKGQRTRKSRSKSADK
KPEELSVTLVEAYTDVFDDTQVEMIDEVTN 
 
TGEV-N amino acid sequence 
MANQGQRVSWGDESTKTRGRSNSRGRKSNNIPLSFFNPITLQQGSKFWNLCPRDFVPKG
IGNRDQQIGYWNRQTRYRMVKGQRKELPERWFFYYLGTGPHADAKFKDKLDGVVWV
AKDGAMNKPTTLGSRGANNESKALKFDGKVPGEFQLEVNQSRDNSRSRSQSRSRSRNR
SQSRGRQQSNNKKDDSVEQAVLAALKKLGVDTEKQQQRSRSKSKERSNSKTRDTTPKN
ENKHTWKRTAGKGDVTRFYGARSSSANFGDSDLVANGSSAKHYPQLAECVPSVSSILF
GSYWTSKEDGDQIEVTFTHKYHLPKDDPKTEQFLQQINAYARPSEVAKEQRKRKSRSKS
AERSEQEVVPDALIENYTDVFDDTQVEMIDEVTN 
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Bovine CoV-N amino acid sequence 
MSFTPGKQSSSRASSGNRSGNGILKWADQSDQSRNVQTRGRRAQPKQTATSQQPSGGN
VVPYYSWFSGITQFQKGKEFEFAEGQGVPIAPGVPATEAKGYWYRHNRRSFKTRDGNQ
RQLLPRWYFYYLGTGPHAKDQYGTDIDGVFWVASNQADVNTPADILDRDPSSDEAIPT
RFPPGTVLPQGYYIEGSGRSAPNSRSTSRASSRASSAGSRSRANSGNRTPTSGVTPDMAD
QIVSLVLAKLGKDATKPQQVTKQTAKEIRQKILNKPRQKRSPNKQCTVQQCFGKRGPNQ
NFGGGEMLKLGTSDPQFPILAELAPTAGAFFFGSRLELAKVQNLSGNLDEPQKDVYELR
YNGAIRFDSTLSGFETIMKVLNENLNAYQQQDGMMNMSPKPQRQRGQKNGQGENDNI
SVAAPKSRVQQNKSRELTAEDISLLKKMDEPYTEDTSEI 
 
Murine hepatitis virus-N amino acid sequence 
MSFVPGQENAGSRSSSGNRAGNGILKKTTWADQTERGNRGRRNHPKQTATTQPNAGSV
VPHYSWFSGITQFQKGKEFQFAQGQGVPIASGIPASEQKGYWYRNRRSFKTPDGQHKQL
LPRWYFYYLGTGPHAGAEYGDDIEGVVWVASQQADTKTTADVVERDPSSHEAIPTKFA
PGTVLPQGFYVEGSGKSAPASRSGSRSQSRGPNNRARSSSNQRQPASAVKPDMAEEIAA
LVLAKLGKDAGQPKQVTKQSAKEVRQKILTKPRQKRTPNKQCPVQQCFGKRGPNQNFG
GSEMLKLGTSDPQFPILAELAPTPSAFFFGSKLELVKKNSGGADEPTKDVYELQYSGAIR
FDSTLPGFETIMKVLTENLNAYQDQAGSVDLVSPKPPRRGRRQAQEKKDEVDNVSVAK
PKSLVQRNVSRELTPEDRSLLAQILDDGVVPDGLEDDSN 
 
 
 
 
 
 
Appendix 
 
133 
 
HIV-1 capsid protein 
PIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTV
GGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGW
MTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQAS
QEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVL 
 
HIV-1 p24 
PIVQNAQGQMIHQSLSPRTLNAWVKVIEEKAFSPEVIPMFSALSEGATPFDLNMMLNIVG
GHQAAMLMLKDTINEEAAEWDRLHPVHAGPVAPGQMREPRGSD 
 
HIV-1 Vpr 
MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETYGDTWAGVE
AIIRILQQLLFIHFRIGCRHSRIGVTRQRRARNGASRS 
 
HIV-1 heparan 
MGARASVLIGGKLNPWEKIRLRPGGKKKYRLKLLVWASRELERFALDSGLLETSQGCQ
QIMEQLQPALRTGTGDLNSLFNTVATLWCVHQRIEVKDTKEALDKIEEIPNKKKPQQAA
ADTGSNSKVSQNYPIVQNAQGQMAYQSISPRTLNAWVKAIEEKAFSPEVIPMFTALSEG
ATPQDLNMMLNIVGGHQAAMQMLKDTFNEEAAEWDRVLPVQAGPHPAGQMREPRGS
DIAGTTSTLQEQIGWMTSNPPIPVGEIYKRWIVLGLNKIVRMYSPVSILDIRQGPKEPFRD
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YVDRFFKCLRAEQATQEVKNWMTETLLVQNANPDCKNILKALGPAASLEEMMTACQG
VGGPSHKARVLAEAMSQVHSPNIMMQKGNFRGQKRIKCFNCGKEGHLARNCRAPRKK
GCWKCGKEGHQMKDCTERQANFLGRIWPSSKGRPGNFPQSRLEPTAPPAESFGFGEEIA
PSPKQETKDKELYPLASLKSLFGNDP 
 
HCV NS5A 
SGSWLRDVWDWICTVLTDFKTWLQSKLLPRLPGVPFLSCQRGYKGVWRGDGVMHTTC
PCGAQITGHVKNGSMRIVGPKTCSNTWHGTFPINAYTTGSCTPSPAPNYSRALWRVAAE
EYVEVTRVGDFHYVTGMTTDNIKCPCQVPAPEFFTELDGVRLHRYAPACKPLLRDEVTF
QVGLNQYVVGSQLPCEPEPDVTVLTSMLTDPSHITAETAKRRLARGSPPSLASSSASQLS
APSLKATCTTHHDSPDADLIEANLLWRQEMGGNITRVESENKVVILDSFDPLRAEEDERE
VSVPAEILRKTRKFPSALPIWARPDYNPPLLESWRDPDYVPPVVHGCPLPPTKAPPIPPPR
RKRTVILTESTVSSALAELATKTFGSSGSSAVDSGTATAPPDGPSDDGDAGSDAESYSSM
PPLEGEPGDPDLSDGSWSTVSEEASEDVVCC 
 
HCV NS2 
MDREMAASCGGVVFVGLVFLTMSPHYKVFLARLIWWLQYFLTIAEAHLQVWIPPLNIR
GGRDAIILLTCVIHPELIFDITKLLLATLGPLLVLQAGIARVPYFVRAHGLIRACVLLRKVA
GGHYVQMALMKLAALTGTYLYDHLTPLQYWAHAGLRDLAVAVEPVIFSDMEIKIITWG
ADTAACGDIIQGLPVSARRGREILLGPADSLEGQGWRLL 
 
 
 
 
 
